ANTIBODIES BINDING TO ILT4

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.

ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOF

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Ra). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Determining method and system for second interface cementing quality of cement sheath

The invention provides a determining method and system for second interface cementing quality of a cement sheath. The method comprises the steps that six full waveforms which are received in a short spacing mode and used for measuring the upper portion or the lower portion of a sonic system are selected from 24 waveforms recorded by a cement cementing imaging and logging instrument, wherein a well cementation inner wall is covered with the six selected full waveforms along the propagation path from a transmitter to a receiver by at least one turn, and sub-waves are extracted from the six selected full waveforms respectively; according to the extracted sub-waves, reflected waveforms, from the outer side of the cement sheath, in the six full waveforms are extracted respectively based on the least square deconvolution algorithm, wherein each reflected waveform corresponds to one sector of well cementation; the waveform energy of all the reflected waveforms is calculated, and the cementing ...

Screen testing jig suitable for various screens

The invention relates to the technical field of testing jigs, in particular to a screen testing jig suitable for various screens. The screen testing jig suitable for the various screens comprises a base and a screen fixing device arranged on the base, wherein the screen fixing device is arranged on the upper surface of the base and comprises a positioning groove, and the positioning groove comprises two vertical groove walls with adjustable relative positions. The screen testing jig suitable for the various screens further comprises a plurality of testing ports suitable for the different screens, and the multiple testing ports are formed in the upper surface of the base side by side and located on the side opposite to the side where the screen fixing device is located. The one screen testing jig can be suitable for testing the various screens different in type, and is simple in structure and convenient to use and operate.

Bathroom cabinet

The utility model discloses a bathroom cabinet, its technical scheme main points are: the intelligent cabinet temperature adjusting device comprises a cabinet body, the internal storing chamber that includes of cabinet, the storing intracavity is provided with the baffle, the baffle is separated the storing chamber and is become to go up storing chamber and storing chamber down, the quantity of baffle is two, including first transparent plate and second transparent plate, form interlayer cavity between first transparent plate and the second transparent plate, be equipped with the bactericidallamp in the interlayer cavity, first transparent plate is articulated with storing intracavity wall, first transparent plate lower extreme is equipped with the supporting mechanism, the supporting mechanism include the horizontal support board and with horizontal support board articulated movable supporting plate, when first transparent plate is in horizontal position, the horizontal support boardis ...

Anti-flameout control method and device under emergency braking, automobile and storage medium

The invention relates to the technical field of vehicles, and discloses an anti-flameout control method and device under emergency braking, an automobile and a storage medium. The method comprises the steps that when it is detected that a vehicle is in a running state, the braking acceleration value and the braking master cylinder pressure value of the vehicle are obtained; according to the braking acceleration value and the braking master cylinder pressure value, if it is detected that the vehicle is in a medium braking state or an emergency braking state, a torque reserve value is obtained, and torque control is conducted on the vehicle based on the torque reserve value; and the rotating speed change rate of the vehicle is obtained, a proportional control coefficient is obtained according to the rotating speed change rate, and engine rotating speed control is conducted on the vehicle based on the proportional control coefficient. According to the technical scheme of the embodiment, the ...

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Method and apparatus for predicting and controlling photovoltaic power generation capacity by improving similar day

The present disclosure provides a method and apparatus for predicting and controlling a photovoltaic power generation capacity by improving a similar day. The method includes: acquiring weather forecast information of multi-consecutive days to be predicted after a present date; obtaining, according to historical weather information with an SVM model, a historical power generation capacity of a photovoltaic system, and the weather forecast information of the multi-consecutive days to be predicted, a predicted power generation capacity of each day to be predicted; obtaining a total predicted power generation capacity according to multiple predicted power generation capacities; and determining a daily power consumption capacity of the photovoltaic system according to the total predicted power generation capacity and a power storage capacity of the photovoltaic system. The present disclosure predicts the power generation capacity of the photovoltaic system, and controls the power consumption ...

Drug rehabilitation proprietary Chinese medicine

The invention relates to a Chinese traditional patent medicine which can alleviate and inhibit the symptoms of drug addiction attack and has the functions of detoxification, expulsion of toxin, rehabilitation and promoting the recovery of a damaged body. The invention is processed and prepared by rhizoma gastrodiae, earthworm, uncaria, salvia miltiorrhiza, rhizoma corydalis, hemlock parsley, draconic dentes, angelica, acanthopanax,ginseng, liquoric root, pearl powder and bezoar according to proportion; the invention has the functions of calming the liver, dispelling wind, activating blood circulation, removing blood stasis, nourishing blood, soothing the nerves and clearing away heat and toxic material. The invention is a pure Chinese medicine preparation, does not contain any narcotic, and has no toxic and side effect and addiction; the curative effect is remarkable, and the invention does not belong to the drugs strictly controlled by the nation, thus being suitable to be popularized ...

Antibodies against IL-7R alpha subunit and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Steel construction frame curtain is frame connection structure anyhow

The utility model relates to a steel construction frame curtain is frame connection structure anyhow, including horizontal frame and munnion, the munnion is connected perpendicularly to horizontal frame, the bilateral symmetry of munnion is equipped with L type connecting plate, L type connecting plate is through first fastener fixed connection the munnion, horizontal frame passes through second fastener fixed connection L type connecting plate, on the horizontal frame with be equipped with the matched with depressed area on the connection face of L type connecting plate. The utility model discloses avoided the welding seam that exposes of frame junction anyhow, the welding processes that only crossbeam sink the district can go on in the processing factory, is applicable to the processing of big batch, has reduced on -the -spot installation work volume, has improved efficiency, steel structural framework curtain anyhow the installation of frame connected system with dismantle simply, the ...

Bagged product tightness detection device and method

The invention provides a bagged product tightness detection device and method. The device comprises a vacuum pump, a transition chamber, a detection chamber, a detection platform, a pressure sensor, a first cylinder and a second cylinder; the vacuum pump is connected with the transition chamber through a first pipeline; the transition chamber is connected with the detection chamber through a second pipeline; the pressure sensor is arranged on the inner wall of the detection chamber; the detection chamber used for holding a bagged product to be detected is arranged on the detection platform; the first cylinder and the second cylinder are arranged on two sides of the outer wall of the detection chamber; the first cylinder and the second cylinder jointly influence the detection chamber, so that the detection chamber and the detection platform form a closed space. The bagged product tightness detection device and method has the advantages that detection cost can be decreased, detection speed ...

Laser cutting method and device, computer equipment and storage medium

The invention relates to the field of laser cutting, in particular to a laser cutting method and device, computer equipment and a storage medium. The method comprises the steps that the constant-speed cutting speed, the accelerated cutting acceleration and the decelerated cutting acceleration of a cutting head are obtained; according to the constant cutting speed and the accelerated cutting acceleration, the acceleration distance of the cutting head is determined; the deceleration distance of the cutting head is determined according to the constant cutting speed and the deceleration cutting acceleration; setting an initial cutting extension line according to the cutting intersection point and the acceleration distance; setting a cutting termination extension line according to the cutting intersection point and the deceleration distance; and the cutting head is controlled to conduct laser cutting on the to-be-cut material sequentially along the initial cutting extension line, the preset ...

Circuit board target positioning method and device, electronic equipment and storage medium

The embodiment of the invention provides a positioning method and device for a circuit board target, electronic equipment and a storage medium, which can quickly and accurately position the target position of a circuit board to be processed on the premise of not needing a target template, thereby improving the production efficiency of a printed circuit board. The circuit board target positioning method comprises the following steps: receiving a design drawing file of a circuit board to be processed, and analyzing a theoretical size and a theoretical centroid coordinate of a target target from the design drawing file; obtaining a preset theoretical type and a theoretical shape of the target target; based on the theoretical centroid coordinate, the theoretical type and the theoretical shape, identifying a suspected target in a scanning image corresponding to the to-be-processed circuit board; identifying the actual size of the suspected target; and if the difference value between the actual ...

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 1. An isolated antibody , or antigen binding fragment thereof , that binds to human glucocorticoid-inducible TNF receptor (GITR) and comprises a heavy chain constant region comprising (1) an amino acid sequence selected from the group consisting of SEQ ID NOs: 223-226 , 283-290 , 383-446 and 480-543 or (2) a heavy chain constant region that differs therefrom in at most 5 amino acids or is at least 95% , 96% , 97% , 98% or 99% identical to an amino acid sequence of SEQ ID NOs: 223-226 , 283-290 , 383-446 and 480-543 , wherein the amino acid modification(s) are not at the specific amino acid(s) in SEQ ID NOs: 223-226 , 283-290 , 383-446 and 480-543 that are not present in the naturally-occurring human heavy chain constant regions.2. The antibody claim 1 , or antigen binding portion thereof claim 1 , of claim 1 , wherein the antibody stimulates an anti-tumor immune response.3. The antibody claim 1 , or antigen binding portion thereof claim 1 , of or claim 1 , wherein the antibody stimulates an antigen-specific T cell response.4. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody increases IL-2 and/or IFN-γ production in GITR-expressing T cells.5. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody increases T cell proliferation.6. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the ...

Antibodies binding to VISTA at acidic pH

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Airtightness test fixture

The invention discloses an airtightness test fixture. The airtightness test fixture comprises a fixture frame, a control panel arranged in the fixture frame, test seats installed on the upper surface of the fixture frame, and air pressure monitors for detecting air pressure change inside an electronic component to be tested, wherein the test seats are connected with air inlet pipes and have air inlets communicating with the electronic component to be tested formed therein, the air pressure monitors are electrically connected with the control panel, and the fixture frame is also provided with displays and indicating lamps which are controlled by the air pressure monitors. The airtightness test fixture has the following advantages: a conventional bubble detection method in the prior art is replaced, and under the condition that external air pressure is not changed, the airtightness of the electronic component is tested through detecting the air pressure change inside the electronic component ...

Automatic welding system and automatic plate welding clamp thereof

According to the automatic welding system and the automatic plate welding clamp thereof, the automatic plate welding clamp is simple in structure, and a welded plate can be rapidly adjusted to the position where automatic welding can be achieved. The automatic welding system comprises the automatic plate welding clamp. In order to achieve the purpose, the automatic plate welding clamp comprises abase, a plurality of elastic elements and a plurality of pressing claw pieces. The pressing claw pieces apply pressure to the plate above the corresponding elastic elements, so that the elastic elements are pressed, and the supporting height of the corresponding plate is jointly limited by the pressing claw pieces and the corresponding elastic elements; and the supporting height is adjusted through the pressing claw piece.

Watch waterproof performance test jig

The invention discloses a watch waterproof performance test jig which comprises a base and a rear support. The jig is characterized by further comprising a cylinder, a pressing mechanism, a probe, a containing block and a liquid container, wherein the top of the rear end of the base is provided with the rear support, the front of the rear support is connected with the cylinder, the bottom of a cylinder rod of the cylinder is connected with the pressing mechanism where the probe is arranged, the base under the probe is provided with the containing block used for containing a watch main panel, the inside of the containing block is provided with a containing cavity used for allowing water to flowing in, and the base is provided with the liquid container in through connection with the containing cavity through a pipeline. The jig solves the problems that when a waterproof performance test is carried out on the electronic watch main panel in the prior art, a testing mechanism is complicated, ...

Cold and hot water exchanging and circulating device of water heater

The invention discloses a cold/hot water displacement circulating device for a water heater, which includes a sleeve circulating pump and a sleeve. A water inlet external pipe interface (5) and a water outlet external pipe interface (6) of the sleeve circulating pump are respectively connected with a water device (10) via the sleeve and a water storage tank (9) of the water heater to form the cold/hot water displacement circulating device. The cold/hot water displacement circulating device has simple structure and low cost, and can be matched with a solar water heater, a boiler and other various water heating systems in different manners, thereby achieving the purposes of water-saving and convenient usage.

Valve structure with adjustable maximum opening degree

The invention provides a valve structure with the adjustable maximum opening degree, and relates to the technical field of valve structures. A pump machine is installed at the top end of a base, a connecting pipe is installed on the left side of the pump machine, the other end of the connecting pipe is connected with a guide seat, a longitudinal groove is formed in the right side of the guide seat, and a row of guide plates are fixedly connected to the interior of the longitudinal groove in a linear array mode; the problems that the opening degree of a valve is mostly of a fixed and non-adjustable structure, so that the valve cannot carry out corresponding adjustment operation when controlling different fluids, a valve body is easily damaged when the opening and closing of the valve are controlled purely depending on the pressure of the fluids, and then limitation exists are solved. A pressure sensor abuts against the guide seat for limiting and supporting, and after adjustment of an electric ...

ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody. 1. An antibody that specifically binds to human MHC class I polypeptide-related sequence A (MICA) and/or human MEW class I polypeptide-related sequence B (MICB) , comprising a heavy chain variable region (VH) and a light chain variable region (VL); wherein the VH comprises a VH complementarity determining region (CDR) 1 , a VH-CDR2 , and a VH-CDR3 and the VL comprises a VL-CDR1 , a VL-CDR2 , and a VL-CDR3; wherein the VH-CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 , 17 , 27 , 37 , and 47.2. The antibody of claim 1 , wherein:(a) the VH-CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 16, 26, 36, and 46;(b) the VH-CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 15, 25, 35, and 45;(c) the VL-CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 18, 28, 38, and 48;(d) the VL-CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 29, 39, and 49;(e) the VL-CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 20, 30, 40, and 50; orany combination of (a)-(e).36-. (canceled)7. The antibody of claim 1 , wherein(a) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:8, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:9, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:10;(b) the VH-CDR1 comprises the amino acid ...

ANTIBODIES AGAINST CD73 AND USES THEREOF

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers. 162-. (canceled)63. A method of decreasing adenosine levels in a tumor of a human subject , comprising administering to the subject an antibody , or antigen binding portion thereof , that binds to human CD73 , wherein the antibody , or antigen binding portion thereof , comprises a heavy chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 5 , 6 , and 7 , respectively , and a light chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 13 , 14 , and 15 , respectively.64. A method of stimulating an immune response against a tumor in a human subject in need thereof , comprising administering to the subject an effective amount of an antibody , or antigen binding portion thereof , that binds to human CD73 , wherein the antibody , or antigen binding portion thereof , comprises a heavy chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 5 , 6 , and 7 , respectively , and a light chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 13 , 14 , and 15 , respectively.65. A method of stimulating an immune response in a human subject comprising ...

Circuit cutting tool of PCB (Printed Circuit Board)

The invention discloses a circuit cutting tool of a PCB (Printed Circuit Board). The circuit cutting tool comprises an arc-shaped plastic housing; the front end of the plastic housing is provided with a rectangular gap which is used for installing a cutting tool bit; a stainless steel plate which is in a concave surface shape is arranged in the rectangular gap; the outer edge of the stainless steel plate is vertically bent downward to form a gap which is used for clamping the cutting tool bit; the cutting tool bit is connected into the gap in an inserting mode; the outer side of the cutting tool bit is provided with a fixing plate which is used for fixing the cutting tool bit in the stainless steel plate through a bolt; the cutting tool bit comprises the tool bit portion and the installing portion which are integrally formed; the rear end of the installing portion is in a rounded rectangle shape and is connected into the gap in an inserting mode; a 135 degree of included angle is formed ...

Low-dielectric material lapping liquid

The invention discloses a low dielectric material polishing liquid, comprising: grinding medium, rate modifier with carboxyl group, non-ferrous oxidant and inhibitor agent excepting benztotriazole, the pH value is 7 to 13. The polishing liquid has a high polishing rate to CDO (carbon-doped silica) and Ta. The low dielectric material polishing liquid has the advantages of better corrosion inhibitor effect than benztotriazole, and stronger repairing effect to drawbacks caused in the process of preorder preparation of wafer.

Construction method of prestressed suspension type building structure

The present invention provides a construction method of a prestressed suspended building structure. The method includes six steps: (1) vertical bearing structures are mounted on a foundation, that is, stiff steel frameworks are mounted in core tube shear walls; (2) a cantilevered bearing structure is mounted on the vertical bearing structures and is a cantilevered steel truss, meanwhile, the supporters of a suspended floor structure are erected, and then the suspended floor structure is mounted on the erected supporters; (3) after the cantilevered steel truss is connected with the upmost suspenders of the suspended floor structure, prestressed cables are mounted in the cantilevered steel truss and the suspenders and initially tensioned; (4) the supporters of the suspended floor structure are dismounted, so that the suspended floor structure is suspended on the cantilevered bearing structure by the suspenders and the prestressed cables in order to form a real suspended structure system; ...

Fingerprint identification module laminating structure

The utility model relates to a fingerprint identification module laminating structure, including the flexible circuit board, with flexible line way board keep electrical connection the chip and through the becket that conductive silver adhesive and flexible line way board are connected, put between chip and the flexible line way board that to be filled with the packing gluey, wherein, still have the screening glass through gluey laminating of laminating on the chip. Use this laminating mechanism, can simplify fingerprint identification module production processes, reduce material cost, can also improve fingerprint identification's effect.

Laser cutting method

The invention relates to the technical field of rigid-flex boards, and discloses a laser cutting method, the laser cutting method is used for cutting a single rigid-flex board on a whole board, the rigid-flex board is provided with a flexible area and a rigid area adjacent to the flexible area, and the rigid-flex board is provided with a boundary line. The boundary line includes a rigid region boundary line formed by the rigid region. The laser cutting method comprises the steps that a laser processing device conducts laser cutting on the whole plate along the boundary line of the rigid area and conducts laser cutting on the whole plate along the boundary line; according to the technical scheme, the technical problem that in the prior art, when the rigid-flex board is cut and formed, the rigid-flex board is prone to displacement in the remaining cutting process due to the fact that part of the rigid-flex board is cut, and then the cutting quality is affected is solved, meanwhile, local ...

Spraying control method for submarine cable laying machine

The invention relates to a spraying control method for a submarine cable laying machine. The spraying control method comprises the following steps: acquiring a relational expression between the ground breaking depth and the diameter of a nozzle, the soil layer strength, the spraying speed of the nozzle, the horizontal moving speed of the nozzle and the sprayed water flow pressure; the known soil layer strength and the preset ground breaking depth are substituted into the relational expression, and conditions needing to be met among the diameter of the nozzle, the spraying speed of the nozzle, the horizontal movement speed of the nozzle and the sprayed water flow pressure are obtained through calculation; the cable laying machine carries out construction according to the calculated parameters; and finally, the actual ground breaking depth is compared with the preset ground breaking depth, and the current cable laying machine can meet the construction requirement by increasing or decreasing ...

Energy-saving spraying equipment and spraying method thereof

The energy-saving type spraying equipment comprises two cross beam mounting frames, a plurality of transmission rollers, a spraying cover body and an integrated connecting box body, a first liquid storage box, a second liquid storage box and a waste liquid recycling box are movably mounted in the integrated connecting box body, and the waste liquid recycling box is arranged between the first liquid storage box and the second liquid storage box; the top end of the waste liquid recycling box communicates with a liquid discharging valve, a metal conveying pipeline is fixedly connected to a feeding opening of the closed pipe base, the first liquid suction pipe and the second liquid suction pipe communicate with the first liquid storage box and the second liquid storage box correspondingly, a negative pressure suction pipe is installed at the top end of the spraying cover body, and one end of the negative pressure suction pipe is connected with an assembly type peculiar smell adsorption device ...

Vehicle gear shifting rule selection method and device, electronic equipment and storage medium

The embodiment of the invention discloses a vehicle gear shifting rule selection method and device, electronic equipment and a storage medium. The method comprises the following steps: determining GPF regeneration charking efficiency values of all preset working condition intervals under preset standard cycle working conditions; according to each GPF regeneration charking efficiency value, selecting a target working condition interval meeting a charking efficiency condition from each preset working condition interval; under the condition that the number of the target working condition intervals is multiple, working condition point proportions of different reference gear shifting rules in the target working condition intervals are determined; and based on the ratio of each working condition point, selecting a reference gear shifting rule with the highest ratio of the working condition points from different reference gear shifting rules as a target gear shifting rule with the highest charcoal ...

Bispecific antibodies and methods of using the same

ANTIBODIES AGAINST CD73 AND USES THEREOF

IP-10 ANTIBODIES AND THEIR USES

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases. 1. (canceled)2. A method of treating an inflammatory or autoimmune disease in a subject in need of treatment comprising administering to the subject the antibody , or antigen-binding portion thereof , that binds human IP-10 , such that the inflammatory or autoimmune disease in the subject is treated , wherein the antibody comprises heavy and light chain variable regions , wherein the heavy chain variable region comprises the CDR1 , CDR2 , and CDR3 regions from the heavy chain variable region of SEQ ID NOs: 16 , 28 , 40 , 52 , 64 , 76 , 88 , 100 , 112 , 124 , 136 , or 148.3. (canceled)4. The method of claim 2 , wherein the heavy chain CDR1 claim 2 , CDR2 claim 2 , and CDR3 regions respectively comprise the amino acid sequences of:(a) SEQ ID NOs: 13, 14, and 15;(b) SEQ ID NOs: 25, 26, and 27;(c) SEQ ID NOs: 37, 38, and 39;(d) SEQ ID NOs: 49, 50, and 51;(e) SEQ ID NOs: 61, 62, and 63;(f) SEQ ID NOs: 73, 74, and 75;(g) SEQ ID NOs: 85, 86, and 87;(h) SEQ ID NOs: 97, 98, and 99;(i) SEQ ID NOs: 109, 110, and 111;(j) SEQ ID NOs: 121, 122, and 123;(k) SEQ ID NOs: 133, 134, and 135; or(1) SEQ ID NOs: 145, 146, and 147.5. (canceled)6. The method of claim 4 , wherein the light chain variable region comprises the CDR1 claim 4 , CDR2 claim 4 , and ...

Anti-TREM-1 antibodies and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Antibodies binding to ILT4

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies against MICA and/or MICB and uses thereof

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

TL1A ANTIBODIES AND USES THEREOF

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

Polyurethane gravel pile and construction technology and application thereof

Provided is a polyurethane gravel pile. Holes are formed in a foundation, gravel aggregates are filled into the holes, and polyurethane reaction raw material slurry is poured. After the polyurethane foam reaction raw material slurry is injected into the gravel aggregates, a reaction occurs instantly, the clearances of the gravel aggregates are filled, the polyurethane foam reaction raw material slurry is solidified into polyurethane foam, the pile is bonded with the gravel aggregates and the polyurethane foam in the foundation, the pile is in a waist drum shape, and the polyurethane gravel pile has the advantages of being high in single pile bearing capacity, small in post-construction settlement, strong in bending resistance, simple and fast in construction, short in project period, free of hole shrinkage and pile breakage quality accidents and the like.

Dispensing jig used for assembling backlight lamp

The invention discloses a dispensing jig used for assembling a backlight lamp. The dispensing jig comprises a dispensing barrel and a support, and is characterized in that a bracket is arranged above the support; the dispensing barrel is fixed on the bracket; the dispensing barrel is connected with a pneumatic pump through a breather pipe; the pneumatic pump is connected with a controller. The dispensing barrel is connected with the pneumatic pump through the breather pipe, and the pneumatic pump is connected with the controller which controls air pressure in the dispensing barrel, so that the amount of discharged glue is controlled, and the yield of the product is improved.

Hydraulic overflow energy recycling system

The invention discloses a hydraulic overflow energy recycling system. The hydraulic overflow energy recycling system comprises a hydraulic oil tank, a hydraulic pump, a hydraulic reversing valve and a hydraulic oil cylinder which are connected in sequence, and further comprises a first-level overflow valve, a second-level overflow valve and a first one-way valve, wherein the first-level overflow valve and the second-level overflow valve are connected to the part between the oil returning port of the hydraulic reversing valve and the hydraulic oil tank, the oil inlet of the first one-way valve is connected to the part between the first-level overflow valve and the second-level overflow valve, the oil outlet of the first one-way valve is connected with an energy accumulator and the oil inlet of a second one-way valve, and the oil outlet of the second one-way valve is connected with a pipeline between the hydraulic pump and the hydraulic reversing valve. Overflowing hydraulic oil enters the ...

Grease proofing dirty tap

The utility model discloses a grease proofing dirty tap, its structure includes the tap main part, the switch, the outlet pipe, the delivery port, a filter, grease proofing cloth, no. Two filters, thefilter ware body, the filter delivery port, water inlet of the filter, tap main part top front end be equipped with the switch and with switch swing joint, tap main part top is equipped with a filterand is connected with a filter, a filter is by the filter ware body, filter delivery port and water inlet of the filter constitute, the filter ware body is connected with the tap bulk phase through water inlet of the filter, the filter ware body is connected with the outlet pipe through the filter delivery port. The utility model discloses a grease proofing dirty tap, through having set up the double filtration ware, reinforcing tap filterability has increased the security, and the quality of water of having solved prior art tap play water is not good, unhygienic, and filterability problem inadequately ...

Charging and discharging control method and device of vehicle-mounted battery, vehicle and storage medium

The invention discloses a charging and discharging control method and device for a vehicle-mounted battery, a vehicle and a storage medium. The current charge state of the vehicle-mounted battery can be obtained; determining a partition where the current charge state is located from preset charge partitions to obtain a target charge partition; determining a charging and discharging strategy corresponding to the target charge partition; and controlling the vehicle-mounted battery to charge and discharge according to the charging and discharging strategy According to the method, the vehicle battery can be partitioned, the charging and discharging strategy of the battery is controlled according to the determined partitions, the vehicle battery can be protected, the battery is prevented from being damaged by over-charging or over-discharging, the vehicle can run according to the proper charging and discharging strategy, and the dynamic property, economical efficiency and safety of the whole ...

Anti-NKG2A antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies ( ...

ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

ANTIBODIES BINDING TO VISTA AT ACIDIC PH

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Concave plate type electromagnetic oven

The utility model discloses a concave plate type electromagnetic oven belongs to the kitchen cooking appliances field, has solved the problem that current concave plate type electromagnetic oven upper cover received heat altered shape, damage easily, the utility model discloses a concave plate type electromagnetic oven includes upper cover and spill panel, the spill panel mounting is in on cover, concave plate type electromagnetic oven is still including thermal -insulated circle, combination department of upper cover and spill panel is passed through thermal -insulated circle separates. The embodiment of the utility model provides a mainly used electromagnetism stove, especially concave plate type electromagnetic oven.

Flexible mechanical arm of rubber tapping robot

The utility model discloses a flexible mechanical arm of a rubber tapping robot, which comprises a base, a front arm assembly and a rear arm assembly, and adopts two telescopic degrees of freedom andthree rotational degrees of freedom to enable the mechanical arm to have a working space suitable for rubber tapping operation; the mechanical arm is hydraulically driven and has enough load capacityso as to carry a heavy execution tail end; in order to protect the mechanical arm and the rubber tree from being damaged, a flexible spring damping device is arranged on the mechanical arm, so that counter-acting force and vibration generated during rubber tapping operation can be effectively reduced. The mechanical arm has certain flexibility and accuracy; the safety and the stability of the whole mechanical arm system are ensured; the flexible mechanical arm provided by the utility model is not only suitable for the field of rubber tapping, but also can be used for some work needing dampingmeasures ...

ANTI-NKG2A ANTIBODIES AND USES THEREOF

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Barrier-free folding chain elevating platform

The invention relates to a barrier-free folding chain elevating platform. The barrier-free folding chain elevating platform comprises a doorframe guide rail fixed to a vehicle or the end face of a corresponding wall of a building, wherein the doorframe guide rail is provided with a pull rod which can move up and down along the doorframe guide rail; the upper end of the pull rod is connected with a lifting mechanism, while the lower end is connected with a foldable pedal device; the pull rod is provided with a foldable handrail device; and the lifting mechanism is connected with an electric control mechanism. The invention solves the problem of large occupied area and also brings convenience to the transportation. A double-insurance facility for folding and positioning the pedal and limiting a folding protection plate on the elevating platform effectively ensures the safety of the elevating platform in the transportation process. The pedal is provided with a turning plate and a ribbed plate ...

Polishing solution used for polishing low-dielectric materials

The invention discloses a polishing liquid of low-dielectric material, which comprises the following parts: grinding material, water, one or more metal chelant, azole film former and oxidant. The invention has higher removing velocity of low-dielectric material and fitful polishing selecting rate of other materials, which displays good surface fineness after polishing.

Application of aromatic compounds in preparing Caspase 3 inhibitor

The invention discloses an application of aromatic compounds in preparing a Caspase 3 inhibitor which is used in preparing drugs for curing diseases such as neurodegenerative diseases, ischemic symptoms, sepsis and the like caused by Caspase 3 over expression, wherein the neurodegenerative diseases refer to Alzheimer's disease, parkinsonism or Huntington's disease; and the ischemic symptoms refer to stroke or myocardial infarction. The aromatic compounds can be obtained by fermenting and separating actinomycetes.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Combination therapy with anti-CD73 antibodies

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.

Combination therapy with anti-CD73 antibodies

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.

Antibodies against TIM3 and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

ANTIBODIES BINDING TO VISTA AT ACIDIC PH

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

ANTIBODIES AGAINST TIM3 AND USES THEREOF

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

ANTIBODIES AGAINST CD73 AND USES THEREOF

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Polishing slurry for low dielectric material

The invention discloses a polishing slurry for a low dielectric material including Al-doped silica and water, which is characterized in that, it further contains active micro-molecule materials which are ammonium-ion or quaternary ammonium ion containing compound. The present polishing slurry has promotion on polishing low dielectric material such as CDO and TEOS or SiON etc., while it has littleeffect on polishing speed for Ta and Cu. Thus it can greatly improve the polishing selectivity for substrates. Moreover, the present polishing slurry can greatly decrease the surface defects such as scratch, corrosion, pitting erosion and the like.

Backwashing device of desulfurizing absorption tower tray beam

The invention discloses a backwashing device for a tray beam of a desulfurizing absorption tower, which comprises a mounting unit and a backwashing unit, the connecting unit comprises mounting plates arranged at the top ends of the supporting rods respectively, conductive blocks arranged on the two mounting plates respectively, and a connecting wire arranged between the two conductive blocks; and the clamping unit comprises clamping assemblies which are respectively arranged on the two mounting plates and are matched with the conductive blocks, and a driving assembly which is arranged on the supporting rod and is connected with the clamping assemblies. According to the backwashing device for the tray beam of the desulfurizing absorption tower, the two clamping assemblies are lifted through the two supporting frames, heavy pressing plates of the clamping assemblies are matched with conductive blocks, a sleeve of a transformer is clamped and fixed, the conductive blocks make contact with ...

ANTIBODIES AGAINST CD73 AND USES THEREOF

Antibodies against CD73 and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against CD73 and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Antibodies binding to VISTA at acidic pH

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Ultrasonic spraying device used for mopping robot

The invention provides an ultrasonic spraying device used for a mopping robot. The ultrasonic spraying device comprises a water tank, and the water tank is arranged on the mopping robot, internally provided with at least one ultrasonic module and a fan, and externally connected with a water outlet pipe and a spray head; water in the water tank is atomized through electronic high-frequency oscillation by the ultrasonic modules, and water mist is blown to a connector of the water outlet pipe through the fan and is sprinkled to the ground through the spray head.

Ice block carrying system of ice factory

The invention relates to an ice block carrying system of an ice factory. The ice block carrying system comprises multiple ice modules (1) which receive ice blocks and can be moved into an ice block repository (5), an ice block grabbing mechanism (3) and an ice block grabbing tool lifting mechanism (4) are arranged in the ice block repository (5), the ice block grabbing mechanism (3) is used for grabbing ice blocks, the ice block grabbing tool lifting mechanism (4) is installed on a traveling crane so as to be used for lifting and moving the ice block grabbing mechanism (3), a large chain way conveying mechanism (6) and a small chain way conveying mechanism (7) are further arranged in the ice block repository (5), the large chain way conveying mechanism (6) is used for conveying ice blocks placed on the large chain way conveying mechanism (6) to the small chain way conveying mechanism (7), and the small chain way conveying mechanism (7) is used for conveying ice blocks out of the ice block ...

Beam shaping method and beam shaping device

The invention belongs to the technical field of laser application, and particularly relates to a beam shaping method and a beam shaping device.The beam shaping method comprises the steps that Gaussian beams are expanded and collimated through a zoom beam expander; the collimated Gaussian beam vertically enters the beam shaper by taking the pre-alignment mark on the beam shaper as a target; a light spot analyzer is arranged in the transmission direction of the light path, and a light spot image, an X-axis energy curve and a Y-axis energy curve are obtained through the light spot analyzer; adjusting the magnification of the zoom beam expander and/or the position of the beam shaper in the X-axis direction and the Y-axis direction; taking a normal from the center of the light spot to the corresponding axis as a symmetry axis, and finishing debugging when a difference value between any two symmetrical points is smaller than a preset value. The magnification of the zoom beam expander is adjusted ...

Electric automobile adopting battery cell module supporting mechanism

The invention discloses an electric automobile adopting a battery cell module supporting mechanism, which comprises a bracket fixing piece, a battery cell module supporting mechanism and a battery cell module supporting mechanism, the buffering cotton is fixed to the two sides of the support fixing piece, and two installation concave positions are arranged on the left side and the right side in the support fixing piece; the first battery pack and the second battery pack are correspondingly arranged in the mounting concave positions respectively; the inner supporting mechanism is embedded and fixed in the support fixing piece, and the first battery pack and the second battery pack are both installed in the inner supporting mechanism; the battery cooling liquid is filled in the inner supporting mechanism in a flowing manner; and the upper limiting plate is horizontally erected above the bracket fixing piece.

ANTIBODIES AGAINST TIM3 AND USES THEREOF

Antibodies against cd73 and uses thereof

GLYPICAN-3-BINDING FIBRONECTIN BASED SCAFFOLD MOLECULES

Provided herein are polypeptides which include tenth fibronectin type III domains (Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 Fn3 drug conjugates are also provided. 1. A nucleic acid encoding polypeptide comprising a tenth fibronectin type III (Fn3) domain comprising BC , DE and FG loops , wherein the polypeptide binds specifically to human glypican-3 (GPC3) , and wherein(a) the BC, DE and FG loops comprise SEQ ID NOs: 6, 7 and 8, respectively;(b) the BC, DE and FG loops comprise SEQ ID NOs: 19, 20 and 21, respectively;(c) the BC, DE and FG loops comprise SEQ ID NOs: 32, 33 and 34, respectively;(d) the BC, DE and FG loops comprise SEQ ID NOs: 45, 46 and 47, respectively;(e) the BC, DE and FG loops comprise SEQ ID NOs: 58, 59 and 60, respectively;(f) the BC, DE and FG loops comprise SEQ ID NOs: 71, 72 and 73, respectively;(g) the BC, DE and FG loops comprise SEQ ID NOs: 84, 85 and 86, respectively;(h) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 101, respectively;(i) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 129, respectively;(j) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 156, respectively;(k) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 183, respectively;(l) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 210, respectively;(m) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 237, respectively;(n) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 264, respectively;(o) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 291, respectively; or(p) the BC, DE and FG loops comprise SEQ ID NOs: 99, 100 and 318, respectively.2. The nucleic acid of claim 1 , wherein the nucleic acid encodes a polypeptide comprising an amino acid sequence at least 90% to the amino acid sequence of any one of SEQ ID NOs: 5 claim 1 , 9-18 claim 1 , 22-31 claim 1 , 35-44 claim 1 , 48- ...

Fixing device and jig for screen testing

The invention relates to the technical field of electronic equipment testing, in particular to a fixing device for screen testing. The device comprises a product fixing part and a pulling part connected with the product fixing part. The product fixing part comprises a product fixing plate, a fixing groove is formed in the product fixing plate and used for placing a screen to be tested, and one or more clamping parts for clamping the screen to be tested are arranged in the fixing groove. The invention further provides a jig for screen testing. The jig comprises a testing frame and a testing assembly installed in the testing frame. The fixing device is further arranged in the testing frame and used for screen testing. In the testing process of the screen of an electronic product, friction and collision between the screen and the fixing groove are reduced, meanwhile, one fixing groove can be used for testing screens different in specification, and therefore production cost is reduced. Multiple ...

Transverse frame and mullion pin connection system and connection method for frame curtain wall

The invention relates to a transverse frame and mullion pin connection system and a transverse frame and mullion pin connection method for a frame curtain wall. The transverse frame and mullion pin connection system comprises a transverse frame and a mullion; the mullion is vertically connected with the transverse frame; both ends of the transverse frame are provided with sliding cavities; sliding core inserts are arranged in the sliding cavities; the sliding core inserts are fixedly connected with the mullion by double-ended pins. The invention aims to provide the transverse frame and mullion pin connection system for the frame curtain wall; manufacturing cost of the double-ended pins is lower than that of both a bolt and a spring and are simple to machine; meanwhile, the double-ended pins are solid, are difficult to damage, have long service lives and are difficult to generate the rusting condition; the sliding core inserts are integrated with sliding strips on the outer walls of the ...

Method, terminal and system for transmitting files

The invention discloses a method, terminal and system for transmitting files, and belongs to the field of communication. The method comprises the steps that pictures which are shot by an opposite terminal and contain the files to be transmitted are acquired, and the files to be transmitted in a local terminal are determined according to the pictures; the file paths of the files to be transmitted are determined according to the files to be transmitted; the files to be transmitted are acquired according to the file paths of the files to be transmitted, and the files to be transmitted are transmitted to the opposite terminal. After the pictures which are shot by the opposite terminal and contain the files to be transmitted are acquired through the terminal for transmitting the files, the files to be transmitted in the pictures at the local terminal are determined according to the pictures, the file paths are determined according to the determined files to be transmitted, the to-be-transmitted ...

Memory burning interface circuit and memory burning method

The invention provides a memory burning interface circuit and a memory burning method. The memory burning interface circuit employs at least one burning channel and comprises at least one selection signal generation module for receiving a clock signal and an interference sequence signal respectively and generating a selection signal of the corresponding burning channel, a burning port selection module for receiving the selection signal from the at least one selection signal generation module and switching on the corresponding burning channel according to the selection signal, and a burning control module for receiving the clock signal, a burning mode sequence and a burning data sequence from the burning port selection module and generating a burning mode signal and a burning control signal, wherein the at least one selection signal generation module comprises an interference sequence decoding module which is used for decoding the interference sequence signal and comparing the decoded interference ...

Chemico-mechanical polishing solution for barrier layer

The invention discloses chemical mechanical polishing slurry for polishing a barrier layer, comprising grinding particles, an oxidizing agent, a film forming agent, an organic chelating agent, a stabilizing agent and water. The polishing solution of the invention has high removal rate of Ta/TaN, is adaptable to the requirements on removal rate selection ratios of capping materials (like TEOS), insulating layer materials (like BD) and metal Cu in different polishing steps, and can ensure less pollutants and defects on the surface of wafers after the polishing as well as high stability.

Gear shifting control method and device, vehicle and storage medium

The invention discloses a gear shifting control method and device, a vehicle and a storage medium. The method comprises the steps that the historical downshift frequency of a target vehicle in a first preset time period can be obtained; determining a power demand type of the target vehicle in the first preset time period based on the historical downshift frequency in the first preset time period; when the power demand type belongs to the preset demand type, determining a gear shifting strategy of the target vehicle in a second preset time period according to the power demand type of the target vehicle in the first preset time period; and controlling the target vehicle to shift gears according to the gear shifting strategy in a second preset time period, wherein the second preset time period is later than the first preset time period. According to the method, the gear shifting strategy can be automatically adjusted according to the driving power requirements of different vehicle drivers, ...

IP-10 antibodies and their uses

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

TL1A antibodies and uses thereof

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 168-. (canceled)69. An isolated antibody which binds to human glucocorticoid-inducible TNF receptor (GITR) , comprising:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 23, 24, and 25, respectively;(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 36, 37, and 38, respectively;(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 46, 47, and 48, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 66, and 67, respectively;(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 68, 69, and 70, respectively;(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 78, 79, and 80, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 81, 82, and 83, respectively;(g) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 91, 92, and 93, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 94, 95, and 96, ...

TL1A antibodies and uses thereof

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described.

High temperature solar tiled reflecting mirror array architecture

The invention relates to a high temperature solar tiled reflecting mirror array architecture, which belongs to the technical field of high-temperature solar energy, and comprises a plurality of supporting frameworks formed by same components according to needs, wherein each supporting framework comprises a plurality of flange bases (13), a plurality of supporting pipes, a plurality of planar four-way connectors (11), a plurality of planar four-way isolation liner pipes (10) and a plurality of reflecting mirror surface linkage shaft bearing blocks (8), a vertical interconnecting pipe (7), horizontal interconnecting pipes (4) and (5), a reflecting mirror surface linkage shaft (3), a rotating dynamic balance weight adjusting pipe (6), a reflecting mirror surface tray (1), a reflecting mirror surface rotating driving semi-circular tray (14), a DC speed-reducing motor (15), rubber wheels (16) and leveling fixing bolts (12). The reflecting mirror array is formed by ready-made profile pipes made ...

Copper surface marking method and device, storage medium and computer equipment

The embodiment of the invention provides a copper surface marking method and device, a storage medium and computer equipment. The method comprises the steps that a laser drawing file is obtained, filling processing is conducted on a laser graph in the laser drawing file, a filling graph is generated, and the filling graph is a first graph layer; setting the last line of the filling pattern as a repeated line, wherein the repeated line is a second pattern layer; and a laser instruction is sent to laser equipment, the laser instruction comprises the set laser parameters, so that the laser equipment responds to the laser instruction to carry out laser processing on the first pattern layer according to the laser parameters, and laser filling processing is carried out on the second pattern layer. In the technical scheme provided by the embodiment of the invention, the last line filled with the pattern is set as the repeated line, and the repeated line is subjected to laser filling treatment, ...

Intelligent electric actuator with protection function

The intelligent electric actuator with the protection function comprises a bottom plate, two buffering supporting pads are fixedly connected to the top of the bottom plate, damping sliding blocks are fixedly connected to the tops of the buffering supporting pads, and an actuator shell is fixedly connected to the tops of the two damping sliding blocks; a damping mechanism is arranged between the bottom plate and the actuator shell. According to the intelligent electric actuator with the protection function, pressure borne by an actuator shell due to vibration can be buffered by arranging a damping sliding block at the top of a buffering supporting pad, rotating control blocks outside sliding control rods on the two sides of a clamping fixing plate can stably abut against buffering blocks, and meanwhile damping springs are movably connected to the two sides of the sliding control rods; and through the stability of the damping spring, the stable contact between the damping ring and the rotating ...

Gear control method and device, electronic equipment and medium

The invention discloses a gear control method and device, electronic equipment and a medium. The method comprises the steps that the current cruise speed, the current gradient information, the current gear information and the preset cruise speed corresponding to a target vehicle under the cruise working condition are obtained; based on the preset cruising speed, the current cruising speed and the current gradient information, target acceleration is determined, and the target acceleration is used for reducing the opening degree variable quantity corresponding to a virtual pedal in the target vehicle; determining a target torque output by an engine in the target vehicle based on the target acceleration, and determining a target pedal opening degree corresponding to the virtual pedal based on the target torque; according to the method and the device, the target gear information corresponding to the target pedal opening degree is determined, and the current gear information is subjected to ...

Bispecific antibodies and methods of using the same

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against CD73 and uses thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

PCB hot-pressing jig with fixing buffering function

The invention discloses a PCB hot-pressing jig with a fixing buffering function. The PCB hot-pressing jig comprises a hot-pressing table and an air cylinder, and is characterized in that the top of the hot-pressing table is provided with a support plate, the top of the support plate is provided with rotating baffle plates in at least two directions, the rotating baffle plates include barrier strips, flexible shaft sleeves and locating shafts, the barrier strips sleeve the locating shaft through the flexible shaft sleeves, an upper side of the hot-pressing table is provided with a rack, the rack is internally provided with the air cylinder, the bottom of an air cylinder rod of the air cylinder is connected with a pressing plate, the pressing plate passes through guide posts and can move up and down along the guide posts, the bottom of the pressing plate is provided with a buffering base plate, a heating plate is arranged under the buffering base plate, and a heating piece is arranged inside ...

Buried gate valve convenient to maintain and inspect

The utility model discloses a buried gate valve convenient to maintain and inspect. The gate valve comprises a gate valve body and two fixing frames. Clamping plates are placed on the inner walls of the bottoms of the two fixing frames. One end of the top outer wall of the clamping plate is fixedly connected with a fixed plate; the other end of the outer wall of the top of the clamping plate is connected with an adjusting plate through a hinge, the outer wall of the side, facing the adjusting plate, of the fixing plate is connected with two hydraulic rods through hinges, the other ends of thetwo hydraulic rods are connected to the outer wall of one side of the adjusting plate through hinges, and the two hydraulic rods are connected with a synchronous hydraulic system. According to the utility model, the fixing frame, the clamping plate, the adjusting plate, the fixing plate and the hydraulic rod are arranged; when the gate valve body is installed, the clamping plate is clamped betweenthe ...

Steel strip cleaning device

The invention discloses a steel strip cleaning device. The steel strip cleaning device comprises a degreasing tank, a rinsing tank, hydraulic monitors, steel strip transmission wheels and drainage pipes, wherein the steel strip transmission wheels are respectively arranged at corresponding positions in the degreasing tank and the rinsing tank, and a steel strip is sequentially conveyed in the degreasing tank and the rinsing tank through the steel strip transmission wheels; the hydraulic monitors are respectively arranged in the degreasing tank and the rinsing tank, and two sides of the steel strip in the degreasing tank and the rinsing tank are respectively provided with at least one hydraulic monitor; and the drainage pipes are respectively arranged on the bottoms of the degreasing tank and the rinsing tank. The steel strip cleaning device has the advantage of simple structure; and by utilizing a high pressure water reverse-jet cleaning mode, physical and chemical cleaning are realized ...

BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. 1. A bispecific antibody comprising an IL-17A/F binding entity and an IL-23 binding entity , wherein the IL-23 binding entity comprises two pairs of immunoglobulin chains , each pair having one light and one heavy chain , and the IL-17A/F binding entity comprises two Fab fragments each comprising a light chain and the Cand variable regions of a heavy chain , and the Fab fragments of the IL-17A/F binding entity are linked to the C-termini of the heavy chains of the IL-23 binding entity.2. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising a CDR1 having the amino acid sequence of SEQ ID NO:22 claim 1 , a CDR2 having the amino acid sequence of SEQ ID NO:23 claim 1 , and a CDR3 having the sequence of SEQ ID NO:24.3. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising the amino acid sequence of SEQ ID NO:9.4. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a constant domain comprising the amino acid sequence of SEQ ID NO:10.5. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising the amino acid sequence of SEQ ID NO:9 and a constant domain comprising the amino acid sequence of SEQ ID NO:10.6. The bispecific antibody of wherein the heavy chains of the IL-17A/F binding entity comprise a variable domain comprising a CDR1 having the amino acid sequence of SEQ ID NO:25 claim 1 , a CDR2 having ...

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 1. An isolated antibody which binds to human glucocorticoid-inducible TNF receptor (GITR) , comprising:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 23, 24, and 25, respectively;(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 36, 37, and 38, respectively;(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 46, 47, and 48, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 66, and 67, respectively;(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 68, 69, and 70, respectively;(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 78, 79, and 80, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 81, 82, and 83, respectively;(g) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 91, 92, and 93, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 94, 95, and 96, respectively;(h) heavy ...

ANTI-GITR ANTIBODIES FOR CANCER DIAGNOSTICS

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy. 139-. (canceled)40. A chimeric antibody which binds to human glucocorticoid-induced tumor necrosis factor receptor (GITR) and comprises a heavy chain comprising a heavy chain constant region , and a light chain comprising a light chain constant region , wherein the heavy chain comprises heavy chain variable region CDR1 , CDR2 , and CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 5-7 , respectively , and the light chain comprises light chain variable region CDR1 , CDR2 , and CDR3 comprising the amino acid sequences set forth in SEQ ID NOs: 8-10 , respectively , wherein the heavy chain constant region is a non-human constant region.41. The antibody of claim 40 , wherein the non-human constant region comprises a mouse Fc region.42. The antibody of claim 41 , wherein the mouse Fc region is a mouse IgG2a Fc region.43. The antibody of claim 40 , wherein the antibody comprises the heavy and light chain sequences set forth in SEQ ID NOs: 15 and 16 claim 40 , respectively.44. The antibody of claim 40 , wherein the antibody comprises a detectable moiety.45. The antibody of claim 44 , wherein the detectable moiety is selected from the group consisting of: a radiolabel claim 44 , a fluorescent label claim 44 , an enzymatic label claim 44 , biotin claim 44 , a chromophore claim 44 , and an ECL label.46. The antibody of claim 45 , wherein the detectable moiety is a fluorescent label claim 45 , and wherein the fluorescent label is FITC.47. A nucleic acid encoding the heavy chain and light chain of the antibody of .48. An expression vector comprising the nucleic acid of . ...

Dry Dual-Scroll Vacuum Pump

A dry dual-scroll vacuum pump includes a driving assembly and an upper cover located above the driving assembly, wherein the driving assembly includes an output shaft, and a movable disk is eccentrically arranged on the output shaft; two groups of first scroll teeth that are centrally symmetrical are arranged on a side of the movable disk that faces the upper cover; a fixed disk is arranged at a lower end of the upper cover, second scroll teeth that are in one-to-one correspondence with the first scroll teeth are arranged on the fixed disk, and the first scroll teeth are meshed with the second scroll teeth to form a compression cavity; and the upper cover is further provided with an air inlet and an air outlet, which correspond to the compression cavity. 11666246. A dry dual-scroll vacuum pump , characterized by comprising a driving assembly and an upper cover located above the driving assembly , wherein the driving assembly comprises an output shaft () , and a movable disk () eccentrically arranged on the output shaft (); two groups of first scroll teeth () that are centrally symmetrical are arranged on a side of the movable disk () that faces the upper cover;{'b': 4', '23', '24', '4', '24', '23', '5', '1, 'a fixed disk () is arranged at a lower end of the upper cover, second scroll teeth () that are in one-to-one correspondence with the first scroll teeth () are arranged on the fixed disk (), and the first scroll teeth () are meshed with the second scroll teeth () to form a compression cavity; and the upper cover is further provided with an air inlet () and an air outlet (), which correspond to the compression cavity.'}224232121244236. The dry dual-scroll vacuum pump according to claim 1 , characterized in that a tooth tip of each of the first scroll teeth () and the second scroll teeth () is provided with a sealing groove () claim 1 , the sealing groove () is internally provided with an elastic sealing material claim 1 , the first scroll teeth () and the fixed ...

ANTIBODIES AGAINST TIM3 AND USES THEREOF

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof. 180-. (canceled)81. An isolated antibody , which binds to a human TIM3 , comprising: (a1) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41, 122, and 126, respectively, and a light chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 64, 66, and 68, respectively;', '(a2) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41, 122, and 128, respectively, and a light chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 64, 66, and 68, respectively;', '(a3) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41, 46, and 129, respectively, and a light chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 64, 66, and 68, respectively;', '(a4) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41, 46, and 128, respectively, and a light chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 64, 66, and 68, respectively;', '(a5) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41, 46, and 127, respectively, and a light chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 64, 66, and 68, respectively;', '(a6) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41, 46, and 126, respectively, and a light chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 64, 66, and 68, respectively;', '(a7) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41, 124, and 53, respectively, and a light chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 64, 66, and 68, respectively;', '(a8) a heavy chain CDR1, CDR2, and CDR3 of SEQ ID NOs: 41 ...

Antibodies Binding to Vista at Acidic pH

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH. 1. An isolated antibody that binds specifically to human VISTA (hVISTA) in acidic conditions.2. The isolated antibody of claim 1 , which binds specifically to hVISTA in acidic conditions claim 1 , but not significantly in neutral or physiological conditions.3. The isolated antibody of or claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kthat is at least 10 fold lower than its Kin neutral or physiological conditions.4. The isolated antibody of any one of to claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kthat is at least 100 fold lower than its Kin neutral or physiological conditions.5. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kthat is at least 1000 fold lower than its Kin neutral or physiological conditions.6. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in neutral or physiological conditions with a Kof 10M or more.7. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in neutral or physiological conditions with a Kof 10M or more.8. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in neutral or physiological conditions with a Kof 10M or more.9. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kof 10M or less.10. The isolated antibody of any one of - claim 1 , wherein the antibody binds to hVISTA in acidic conditions with a Kof 10M or less.11. The isolated antibody of any one of - claim 1 , wherein the antibody binds to ...

Abrasive articles

An abrasive article can include a body including a bond material and abrasive particles contained within the bond material. The body can include a filler composition. In a particular embodiment, the filler composition can include at least one filler from a first filler class and at least one filler from a second filler class. The first filler class can include pyrite, potassium sulfate (K2SO4), potassium chloride (KCl), and lime (CaO), and a combination thereof, and the second filler class includes basalt, mullite, zinc sulfide (ZnS), barium sulfate (BaSO 4 ), potassium titanate (K 2 O.nTiO 2 ) or a combination thereof. In another particular embodiment, the filler composition can include a second filler class including basalt in a content within a range between 1 wt % and not greater than 30 wt % for a total weight of the body. In another particular embodiment, the filler composition can include a second filler class including zinc sulfide (ZnS) in a content within a range between 1 wt % and not greater than 30 wt % for a total weight of the body. In still another particular embodiment, the filler composition can include a second filler class including barium sulfate (BaSO 4 ) in a content within a range between 1 wt % and not greater than 30 wt % for a total weight of the body. In another particular embodiment, the filler composition can include a second filler class including potassium titanate (K 2 O.nTiO 2 ) in a content within a range between 0.1 wt % and not greater than 30 wt % for a total weight of the body. In another particular embodiment, the filler composition can include a second filler class including mullite in a content within a range between 1 wt % and not greater than 30 wt % for a total weight of the body.

Dicaffeoyl Spermidine Cyclized Derivatives And Use Thereof

The present invention relates to dicaffeoyl spermidine cyclized derivatives and a preparation method and use thereof. Biological activity experiments show that the dicaffeoyl spermidine cyclized derivatives of the present invention have anti-Senile dementia activity and antioxidant activity, and their activity are even better than that of a positive control drug, thus suitable for the prevention and treatment of neurodegenerative diseases such as Senile dementia. 2. The dicaffeoyl spermidine cyclized derivatives or the pharmaceutically acceptable salts thereof according to claim 1 , wherein the pharmaceutically acceptable salts are salts formed by the dicaffeoyl spermidine cyclized derivatives of the formula (I) with an inorganic acid or an organic acid.3. The dicaffeoyl spermidine cyclized derivatives or the pharmaceutically acceptable salts thereof according to claim 2 , wherein the inorganic acid is hydrochloric acid claim 2 , hydrobromic acid claim 2 , sulfuric acid claim 2 , or nitric acid claim 2 , and the organic acid is trifluoroacetic acid claim 2 , acetic acid claim 2 , propionic acid claim 2 , malonic acid claim 2 , butyric acid claim 2 , lactic acid claim 2 , methanesulfonic acid claim 2 , ethanesulfonic acid claim 2 , benzenesulfonic acid claim 2 , p-toluenesulfonic acid claim 2 , maleic acid claim 2 , benzoic acid claim 2 , succinic acid claim 2 , picric acid claim 2 , tartaric acid claim 2 , citric acid claim 2 , or fumaric acid.57.-. (canceled)8. A pharmaceutical composition for preventing and treating degenerative diseases claim 1 , comprising the dicaffeoyl spermidine cyclized derivatives or the pharmaceutically acceptable salts thereof according to as an active ingredient claim 1 , and pharmaceutically acceptable excipients.9. The pharmaceutical composition for preventing and treating degenerative diseases according to claim 8 , wherein the content of the dicaffeoyl spermidine cyclized derivatives or the pharmaceutically acceptable salts thereof ...

IL-17A/F AND IL-23p19 BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. 1. A bispecific antibody comprising an IL-17A/F binding entity and an IL-23 binding entity , wherein the IL-23 binding entity comprises two pairs of immunoglobulin chains , each pair having one light and one heavy chain , and the IL-17A/F binding entity comprises two Fab fragments each comprising a light chain and the Cand variable regions of a heavy chain , and the Fab fragments of the IL-17A/F binding entity are linked to the C-termini of the heavy chains of the IL-23 binding entity.2. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising a CDR1 having the amino acid sequence of SEQ ID NO:22 claim 1 , a CDR2 having the amino acid sequence of SEQ ID NO:23 claim 1 , and a CDR3 having the sequence of SEQ ID NO:24.3. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising the amino acid sequence of SEQ ID NO:9.4. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a constant domain comprising the amino acid sequence of SEQ ID NO:10.5. The bispecific antibody of wherein the light chains of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising the amino acid sequence of SEQ ID NO:9 and a constant domain comprising the amino acid sequence of SEQ ID NO:10.6. The bispecific antibody of wherein the heavy chains of the IL-17A/F binding entity comprise a variable domain comprising a CDR1 having the amino acid sequence of SEQ ID NO:25 claim 1 , a CDR2 having ...

METHOD FOR DETERMINING THE NUMBER OF AVAILABLE SHOTS AND IMAGE-SHOOTING APPARATUS

Embodiments of the present invention provide a method for determining the number of available shots and an image-shooting apparatus. The method includes: determining a current shooting mode; acquiring an average value of a picture size before current shooting in the current shooting mode, where the average value of the picture size is calculated according to storage space occupied by pictures shot before the current shooting in the current shooting mode and the number of the pictures shot before the current shooting in the current shooting mode; and determining, according to currently available storage space and the average value of the picture size, the number of available shots before the current shooting. The technical solution of the present invention improves precision of the determined number of available shots. 1. A method for determining the number of available shots , comprising:determining a current shooting mode;acquiring an average value of a picture size before current shooting in the current shooting mode, wherein the average value of the picture size before the current shooting in the current shooting mode is calculated according to storage space occupied by pictures shot before the current shooting in the current shooting mode and the number of the pictures shot before the current shooting in the current shooting mode; anddetermining, according to currently available storage space and the average value of the picture size before the current shooting in the current shooting mode, the number of available shots before the current shooting in the current shooting mode.2. The method for determining the number of available shots according to claim 1 , wherein the acquiring the average value of the picture size before current shooting in the current shooting mode comprises:acquiring, according to the current shooting mode, a first index value corresponding to the current shooting mode;determining whether the first index value exists in a first ...

Antibodies Binding to Vista at Acidic pH

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH. 1171.-. (canceled)172. An isolated antibody that binds specifically to human VISTA (hVISTA) , wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL) , wherein the VH and VL comprise complementarity determining regions (CDRs) of P1-070976 (SEQ ID Nos: 509-511 and 500-502 , respectively) , P1-070976_H95D (SEQ ID Nos: 512-514 and 500-502 , respectively) , VISTA.4 (SEQ ID Nos: 503-505 and 500-502 , respectively) , P1-065333 (SEQ ID Nos: 506-508 and 500-502 , respectively) , or P1-070976_E97P (SEQ ID Nos: 515-517 and 500-502 , respectively).173. The isolated antibody of claim 172 , wherein the VH comprises an amino acid sequence that is at least 90% identical to the VH of P1-070976 (SEQ ID NO: 474) claim 172 , P1-070976_H95D (SEQ ID NO: 477) claim 172 , VISTA.4 (SEQ ID NO: 492) claim 172 , P1-065333 (SEQ ID NO: 473) claim 172 , or P1-070976_E97P (SEQ ID NO: 478); and/orwherein the VL comprises an amino acid sequence that is at least 90% identical to the VL of P1-070976, P1-070976_H95D, VISTA.4, P1-065333, or P1-070976_E97P (corresponding to SEQ ID NO: 493 or SEQ ID NO: 479).174. The isolated antibody of claim 172 , wherein the VH comprises an amino acid sequence that is at least 95% identical to the VH of P1-070976 (SEQ ID NO: 474) claim 172 , P1-070976_H95D (SEQ ID NO: 477) claim 172 , VISTA.4 (SEQ ID NO: 492) claim 172 , P1-065333 (SEQ ID NO: 473) claim 172 , or P1-070976_E97P (SEQ ID NO: 478); and/orwherein the VL comprises an amino acid sequence that is at least 95% identical to the VL of P1-070976, P1-070976_H95D, VISTA.4, P1-065333, or P1-070976_E97P (corresponding ...

SHOOTING METHOD AND TERMINAL

A shooting method and a terminal. A terminal receives a first indication for opening a camera application, where the camera application is associated with at least one mode plug-in and at least one function plug-in. The terminal displays at least one mode option corresponding to the at least one mode plug-in, for selection by a user. The terminal receives a second indication indicating that the user selects a first mode option. The terminal displays a function option that supports a first mode, for selection by the user. The terminal receives a shooting instruction, and performs shooting based on the first mode and a function that is selected by the user from the displayed function option, where a first mode plug-in corresponding to the first mode and a function plug-in corresponding to the selected function are preloaded. 116-. (canceled)17. A terminal , comprising:a processor;a memory;a camera lens; anda display, whereinthe processor is configured to:receive a first indication for opening a camera application, wherein the camera application is installed on the terminal, the camera application is associated with at least one mode plug-in and at least one function plug-in, each mode plug-in corresponds to one mode, and each function plug-in corresponds to one function;display, by using the display, at least one mode option corresponding to the at least one mode plug-in, for selection by a user;receive a second indication indicating that the user selects a first mode option, wherein the first mode option corresponds to a first mode;display, by using the display, a function option that supports the first mode, for selection by the user, wherein a function that supports the first mode is comprised in at least one function corresponding to the at least one function plug-in; andreceive an indication indicating that the user selects a function from the displayed function option;receive a shooting instruction, andresponse to the shooting instruction, perform shooting by ...

ANTIBODIES AGAINST CD73 AND USES THEREOF

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers. 18-. (canceled)9. A method of decreasing adenosine levels in a tumor of a human subject , comprising administering to the subject an antibody that binds to human CD73 , wherein the antibody comprises a heavy chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 5 , 6 , and 7 , respectively , and a light chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 13 , 14 , and 15 , respectively.10. A method of stimulating an immune response against a tumor in a human subject in need thereof , comprising administering to the subject an effective amount of an antibody that binds to human CD73 , wherein the antibody comprises a heavy chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 5 , 6 , and 7 , respectively , and a light chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 13 , 14 , and 15 , respectively.11. A method of stimulating an immune response in a human subject , comprising administering to the subject an antibody that binds to human CD73 , wherein the antibody comprises a heavy chain comprising CDR1 , CDR2 , and CDR3 sequences ...

ANTIBODIES AGAINST TIM3 AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof. 17-. (canceled)8. An isolated antibody , which binds to human T-cell immunoglobulin and mucin-domain containing-3 (TIM3) , comprising a heavy chain CDR1 , CDR2 , and CDR3 and a light chain CDR1 , CDR2 , and CDR3 , wherein:(a) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 45, 413, and 414, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 69, respectively;(b) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 45, 415, and 416, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 68, respectively; or(c) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 45, 415, and 416, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 419, respectively.911-. (canceled)12. The isolated antibody of claim 8 , comprising a heavy chain variable region (VH) and a light chain variable region (VL) claim 8 , wherein the VH comprises an amino acid sequence which is at least about 80% claim 8 , at least about 85% claim 8 , at least about 90% claim 8 , at least about 95% claim 8 , at least about 96% claim 8 , at least about 97% claim 8 , at least about 98% claim 8 , at least about 99% claim 8 , or about 100% identical to the amino acid sequence set forth as SEQ ID NO: 410 or 411.13. The isolated antibody of claim 8 , comprising ...

ENHANCED MODEL UPDATING USING VECTOR SPACE TRANSFORMATIONS FOR MODEL MAPPING

The present disclosure relates to systems and methods for updating static machine-learning models (e.g., a Doc2Vec model) without needing to retrain the models. More particularly, the present disclosure relates to systems and methods that can be used to add new data to a base model by training a client model using the new data, and transforming the vector space of the client model to align with the vector space of the base model. The base model can then be updated using the realigned client model. As such, the base model can be updated with the new data without needing to retrain the base model, which can be burdensome to processing resources, insecure, and time consuming. 1. A computer-implemented method comprising:accessing a first trained model associated with a first entity, the first trained model having been trained using one or more training data sets, each training data set of the one or more training data sets representing a first set of documents, and the first trained model including N dimensions in a first vector space;accessing a second trained model associated with a second entity, the second trained model having been trained a second set of documents, and the second trained model including the N dimensions in a second vector space;determining a set of overlapping words between the first set of documents and the second set of documents;generating a rotation model using each of the first trained model and the second trained model, the rotation model being configured to transform the second trained model, such that the N dimensions in the second vector space are aligned with the N dimensions in the first vector space;transforming the second trained model using the rotation model, the transformed second trained model representing the N dimensions of the second trained model in the first vector space; andupdating the first trained model using the transformed second trained model.2. The computer-implemented method of claim 1 , wherein generating the ...

GLYPICAN-3-BINDING FIBRONECTIN BASED SCAFFOLD MOLECULES

Provided herein are polypeptides which include tenth fibronectin type III domains (Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 Fn3 drug conjugates are also provided. 1. A polypeptide comprising a fibronectin based scaffold (FBS) comprising BC , DE and FG loops , wherein the polypeptide binds specifically to human glypican-3 (GPC3) with a Kor 1 μM or less , and wherein(a) the BC, DE and FG loops comprise SEQ ID NOs: 6, 7 and 8, respectively;(b) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 6, 7 and 8;(c) the BC, DE and FG loops comprise SEQ ID NOs: 19, 20 and 21, respectively;(d) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 19, 20 and 22;(e) the BC, DE and FG loops comprise SEQ ID NOs: 32, 33 and 34, respectively;(f) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 32, 33 and 34;(g) the BC, DE and FG loops comprise SEQ ID NOs: 45, 46 and 47, respectively;(h) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 45, 46 and 47;(i) the BC, DE and FG loops comprise SEQ ID NOs: 58, 59 and 60, respectively;(j) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 58, 59 and 60;(k) the BC, DE and FG loops comprise SEQ ID NOs: 71, 72 and 73, respectively;(l) at least one of the BC, DE and FG loops comprises 1, 2 or 3 amino acid substitutions relative to the respective BC, DE and FG loops of SEQ ID NOs: 71, 72 and 73;(m) the BC, DE and FG loops comprise SEQ ID NOs: 84, ...

BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. 1215.-. (canceled)216. An isolated bispecific antibody comprising an IL-17A/F binding entity and an IL-23 binding entity , wherein the IL-23 binding entity comprises two pairs of immunoglobulin chains , each pair having one light and one heavy chain , which IL-23 light chain variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO:22 , a CDR2 having the amino acid sequence of SEQ ID NO:23 , and a CDR3 having the amino acid sequence of SEQ ID NO:24 , and IL-23 heavy chain variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO:19 , a CDR2 having the amino acid sequence of SEQ ID NO:20 , and a CDR3 having the amino acid sequence of SEQ ID NO:21 , and wherein the IL-17A/F binding entity comprises two Fab fragments linked to the C-terminus of the IL-23 heavy chain.217. An isolated bispecific antibody comprising an IL-17A/F binding entity and an IL-23 binding entity , wherein the IL-17A/F binding entity comprises a light chain comprising the amino acid sequence of SEQ ID NO:17 and a heavy chain comprising the amino acid sequence of SEQ ID NO:81 , and the IL-23 binding entity comprises a light chain comprising the amino acid sequence of SEQ ID NO:17 and a heavy chain comprising the amino acid sequence of SEQ ID NO:61.218. An isolated bispecific antibody comprising a first binding entity and a second binding entity wherein the first binding entity is an antibody comprising two pairs of immunoglobulin chains; the second binding entity is a Fv unit comprising a heavy chain variable domain and a light chain variable domain , wherein the Fv unit of the second binding entity is positioned between and linked to ...

Antibodies Binding to ILT4

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. The isolated antibody of that specifically binds to human ILT4 (hILT4 or ILT4) , which comprises(a) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 9G4 (SEQ ID Nos: 125-127) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 9G4 (SEQ ID Nos: 128-130);(b) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 9C8 (SEQ ID Nos: 131-133) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 9C8 (SEQ ID Nos: 134-136);(c) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 2H2 (SEQ ID Nos: 137-139) and a VL comprising the VL CDR1, CDR2 and CDR3 of 2H2 (SEQ ID Nos: 140-142);(d) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 2E5 (SEQ ID Nos: 143-145) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 2E5 (SEQ ID Nos: 146-148);(e) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 24E5 (SEQ ID Nos: 149-151) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 24E5 (SEQ ID Nos: 152-154);(f) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 21D9 (SEQ ID Nos: 155-157) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 21D9 (SEQ ID Nos: 158-160);(g) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of 21D9.b (SEQ ID Nos: 155-157) and a VL comprising the amino acid sequence of the VL CDR1, CDR2 and CDR3 of 21D9.b (SEQ ID Nos: 158-160);(h) a VH ...

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 128-. (canceled)29. An isolated antibody which binds to glucocorticoid-inducible TNF receptor (GITR) , comprising:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 36, 37, and 38, respectively;(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 46, 47, and 48, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 66, and 67, respectively;(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 68, 69, and 70, respectively;(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 78, 79, and 80, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 81, 82, and 83, respectively;(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 91, 92, and 93, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 94, 95, and 96, respectively;(g) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 106, 107, and 108, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 109 ...

POLYNUCLEOTIDES ENCODING ANTIBODIES

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same. 1. An isolated nucleic acid molecule encoding a bispecific antibody comprising an IL-17A/F binding entity and an IL-23 binding entity , wherein the IL-23 binding entity comprises two pairs of immunoglobulin chains , each pair having one light and one heavy chain , which light chain variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO:22 , a CDR2 having the amino acid sequence of SEQ ID NO:23 , and a CDR3 having the amino acid sequence of SEQ ID NO:24 , and heavy chain variable domain comprises a CDR1 having the amino acid sequence of SEQ ID NO:19 , a CDR2 having the amino acid sequence of SEQ ID NO:20 , and a CDR3 having the amino acid sequence of SEQ ID NO:21 , and wherein the IL-17A/F binding entity comprises two Fab fragments which are linked to the C-terminus of the heavy chain of the IL-23 binding entity.2. The isolated nucleic acid molecule of claim 1 , wherein the light chains of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising the amino acid sequence of SEQ ID NO:9.3. The isolated nucleic acid molecule of claim 1 , wherein the light chains of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprise a constant domain comprising the amino acid sequence of SEQ ID NO:10.4. The isolated nucleic acid molecule of claim 1 , wherein the light chains of the Fab of the IL-17A/F binding entity and the IL-23 binding entity comprise a variable domain comprising the amino acid sequence of SEQ ID NO:9 and a constant domain comprising the amino acid sequence of SEQ ID NO:10.5. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain ...

A FUEL CELL VEHICLE THERMAL MANAGEMENT SYSTEM WITH COLD START FUNCTION AND CONTROL METHOD THEREOF

A fuel cell vehicle thermal management system with cold start function, which includes a fuel cell stack, an electronic water pump, an electronic thermostat, a cold start heater, a first solenoid valve, a thermal management controller, and the air intake preheating heat exchangers. The electronic water pump, electronic thermostat, cold start heater, and the first solenoid valve are all electrically connected to the thermal management controller. The coolant outlet of the fuel cell stack is connected with the liquid inlet of the electronic water pump, and the liquid outlet of the electronic water pump is connected with the liquid inlet of the electronic thermostat and the liquid inlet of the first solenoid valve. The first liquid outlet of the electronic thermostat is connected with the liquid inlet of the cold start heater. The liquid outlet of the cold start heater is connected with the liquid inlet of the fuel cell stack. The liquid outlet of the first solenoid valve is connected with the liquid inlet of the intake preheating heat exchanger. The liquid outlet of the intake preheating heat exchanger is connected with the liquid inlet of the cold start heater. The invention solves the problems of the cold start of the fuel cell vehicle in a low temperature environment and the preheating of cold air before entering the stack. 1. A fuel cell vehicle thermal management system with cold start function , comprising:a fuel cell stack, an electronic water pump, the electronic thermostat, a cold start of the heater, a first solenoid valve, a thermal management controller, the air intake preheating structure; the electronic water pump, the electronic thermostat, the cold start heater and first solenoid valve are all electrically connected to the thermal management controller; the electronic thermostat includes a liquid inlet, a first liquid outlet and a second liquid outlet; and the air intake preheating structure includes an intake preheating heat exchanger arranged in the ...

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 168-. (canceled)69. A method for inhibiting the growth of tumor cells in a subject , the method comprising administering to the subject an antibody that binds to human glucocorticoid-inducible TNF receptor (GITR) and comprises a heavy chain constant region comprising (1) an amino acid sequence selected from the group consisting of SEQ ID NOs: 223-226 , 283-290 , 383-446 and 480-543 or (2) a heavy chain constant region that differs therefrom in at most 5 amino acids or is at least 95% , 96% , 97% , 98% or 99% identical to an amino acid sequence of SEQ ID NOs: 223-226 , 283-290 , 383-446 and 480-543 , wherein the amino acid modification(s) are not at the specific amino acid(s) in SEQ ID NOs: 223-226 , 283-290 , 383-446 and 480-543 that are not present in the naturally-occurring human heavy chain constant regions.70. The method of claim 69 , wherein the antibody comprises:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 20, 21, and 22, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 23, 24, and 25, respectively;(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 36, 37, and 38, respectively;(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 46, 47, and 48, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;(d) heavy chain ...

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 168-. (canceled)69. An isolated antibody which binds to glucocorticoid-inducible TNF receptor (GITR) , comprising:(a) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 20, 21, and 22, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 23, 24, and 25, respectively;(b) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 33, 34, and 35, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 36, 37, and 38, respectively;(c) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 46, 47, and 48, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 49, 50, and 51, respectively;(d) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 65, 66, and 67, respectively;(e) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 62, 63, and 64, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 68, 69, and 70, respectively;(f) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 78, 79, and 80, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 81, 82, and 83, respectively;(g) heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 91, 92, and 93, respectively, and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 94, 95, and 96, ...

ANTI-CD27 ANTIBODIES AND USES THEREOF

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody. 1. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CD27 and does not block binding of its CD70 ligand as measured by surface plasmon resonance (SPR) or flow cytometry , wherein the antibody or fragment thereof:{'sub': 'D', '(a) binds to human CD27 with a Kof about 100 nM or lower, about 90 nM or lower, about 80 nM or lower, about 70 nM or lower, about 60 nM or lower, about 50 nM or lower, about 40 nM or lower, between about 1 nM and about 100 nM, between about 10 nM and about 70 nM, between about 10 nM and about 50 nM, or between about 40 nM and about 45 nM, and/or'}{'sub': '50', '(b) induces NF-κB and MAPK signaling with an ECof about 0.5 nM or lower, about 0.4 nM or lower, about 0.3 nM or lower, between about 0.005 nM and about 0.5 nM, between about 0.01 nM and about 0.4 nM, or between about 0.02 nM and about 0.25 nM in naïve human T cells stimulated by an anti-CD3 antibody and an anti-CD28 antibody.'}2. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to an epitope located within discontinuous regions spanning approximately amino acid residues 21-41 and 52-57 of human CD27 , a sequence of which is set forth as SEQ ID NO: 1 , as determined by hydrogen-deuterium exchange mass spectrometry (HDX-MS) and/or fast photochemical oxidation of proteins (FPOP) epitope mapping.3. A monoclonal antibody or an antigen-binding portion thereof that specifically binds to human CD27 , which:{'sub': 'H', '(a) comprises a heavy chain variable region (V) comprising a CDR1 comprising consecutively linked amino acids ...

ANTIBODIES AGAINST CD73 AND USES THEREOF

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers. 162-. (canceled)63. An isolated antibody , or antigen binding portion thereof , that binds to human Cluster of Differentiation 73 (CD73) , and comprises a heavy chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 5 , 6 , and 7 , respectively , and a light chain comprising CDR1 , CDR2 , and CDR3 sequences comprising the amino acid sequences of SEQ ID NOs: 13 , 14 , and 15 , respectively.64. The isolated antibody claim 63 , or antigen binding portion thereof claim 63 , of claim 63 , which binds to human CD73 with a Kof 0.1 nM to 10 nM claim 63 , as determined by Surface Plasmon Resonance (SPR).65. The isolated antibody claim 63 , or antigen binding portion thereof claim 63 , of claim 63 , which inhibits the activity of human CD73.66. The isolated antibody claim 63 , or antigen binding portion thereof claim 63 , of claim 63 , which mediates internalization of human CD73.67. The isolated antibody claim 63 , or antigen binding portion thereof claim 63 , of claim 63 , which has reduced effector function relative to a wild type IgG1 antibody.68. The isolated antibody claim 63 , or antigen binding portion thereof claim 63 , of claim 63 , which is a human IgG antibody.69. The ...

ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOF

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody. 1. An antibody that specifically binds to human MHC class I polypeptide-related sequence A (MICA) and/or human MHC class I polypeptide-related sequence B (MICB) , comprising a heavy chain variable region (VH) and a light chain variable region (VL); wherein the VH comprises a VH complementarity determining region (CDR) 1 , a VH-CDR2 , and a VH-CDR3 and the VL comprises a VL-CDR1 , a VL-CDR2 , and a VL-CDR3; wherein the VH-CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 7 , 17 , 27 , 37 , and 47.2. The antibody of claim 1 , wherein:(a) the VH-CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 16, 26, 36, and 46;(b) the VH-CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 15, 25, 35, and 45;(c) the VL-CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 18, 28, 38, and 48;(d) the VL-CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 9, 19, 29, 39, and 49;(e) the VL-CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 20, 30, 40, and 50; or(f) any combination of (a)-(e).36-. (canceled)7. The antibody of claim 1 , wherein(a) the VH-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:5, the VH-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:6, the VH-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:7, the VL-CDR1 comprises the amino acid sequence set forth in SEQ ID NO:8, the VL-CDR2 comprises the amino acid sequence set forth in SEQ ID NO:9, and the VL-CDR3 comprises the amino acid sequence set forth in SEQ ID NO:10;(b) the VH-CDR1 comprises the amino ...

TL1A ANTIBODIES AND USES THEREOF

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. 1. An antibody , or antigen binding fragment thereof , that competes for binding to human TL1A (T cell immunoreceptor with Ig and ITIM domains) with antibody 10A4 , wherein the antibody or fragment substantially inhibits the binding of human TL1A to DR3.2. An antibody , or antigen binding fragment thereof , that binds to TL1A at an epitope comprising one or more of residues 102-116(SEQ ID NO:16) or 166-180(SEQ ID NO: 17).3. The antibody or antigen binding fragment of that binds to TL1A at an epitope comprising one or more of residues QAGRand one or more of residues KNQF.4. The antibody or antigen binding fragment of that binds to TL1A at an epitope comprising the sequence QAGRand/or KNQF.5. The antibody or antigen binding fragment of wherein the antibody or fragment substantially inhibits the binding of human TL to DR3.6. The antibody or antigen binding fragment of or wherein the antibody binds to both human and cynomolgus TL1A.7. The antibody claim 1 , or antigen binding fragment thereof claim 1 , of claim 1 , wherein antibody 10A4 further comprises: i) CDRH1 comprising the sequence of SEQ ID NO.:7;', 'i) CDRH2 comprising the sequence of SEQ ID NO.:8; and', 'i) CDRH3 comprising the sequence of SEQ ID NO.:9;', 'and, 'a) a heavy chain variable domain comprising i) CDRL1 comprising the sequence of SEQ ID NO.:12;', 'i) CDRL2 comprising the sequence of SEQ ID NO.:13; and', 'i) CDRL3 comprising the sequence of SEQ ID NO.:14., 'b) a light chain variable domain comprising8. The antibody or antigen binding fragment of comprising one or more heavy chains and one or more light chains claim 7 , wherein:a) the heavy chain comprises a heavy chain variable region having at least 80% sequence identity with the sequence of SEQ ID NO: 6; anda) the light chain comprises a light chain variable ...

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 128-. (canceled)29. An isolated antibody , or antigen binding portion thereof , which binds to human glucocorticoid-inducible TNF receptor (GITR) , comprising heavy chain CDR1 , CDR2 , and CDR3 sequences comprising SEQ ID NOs: 20 , 21 , and 22 , respectively , and light chain CDR1 , CDR2 , and CDR3 sequences comprising SEQ ID NOs: 23 , 24 , and 25 , respectively , wherein the antibody binds to membrane-bound human GITR.30. The isolated antibody claim 29 , or antigen binding portion thereof claim 29 , of claim 29 , wherein the antibody binds to membrane-bound human GITR with a Kof 10 nM or less as determined by Scatchard analysis.31. The isolated antibody claim 29 , or antigen binding portion thereof claim 29 , of claim 29 , wherein the antibody binds to membrane-bound human GITR with a Kof 1 nM or less as determined by Scatchard analysis.32. The isolated antibody claim 29 , or antigen binding portion thereof claim 29 , of claim 29 , wherein the antibody claim 29 , or antigen binding portion thereof claim 29 , binds to membrane-bound GITR on activated human T cells.33. The isolated antibody claim 29 , or antigen binding portion thereof claim 29 , of claim 29 , wherein the antibody claim 29 , or antigen binding portion thereof claim 29 , binds to membrane-bound GITR on 3A9 cells ectopically expressing human GITR.34. The isolated antibody claim 29 , or antigen binding portion thereof claim 29 , of claim 29 , which is a human antibody or antigen binding portion thereof.35. The ...

Antibodies against cd73 and uses thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

IP-10 ANTIBODIES AND THEIR USES

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases. 1. An isolated monoclonal antibody , or antigen-binding portion thereof , that binds human IP-10 , comprising heavy and light chain variable regions , wherein the heavy chain variable region comprises the CDR1 , CDR2 , and CDR3 regions from the heavy chain variable region of SEQ ID NOs: 16 , 28 , 40 , 52 , 64 , 76 , 88 , 100 , 112 , 124 , 136 , or 148.2. The antibody claim 1 , or antigen-binding portion thereof claim 1 , of claim 1 , wherein the heavy chain variable region comprises the CDR1 claim 1 , CDR2 claim 1 , and CDR3 regions from the heavy chain variable region of SEQ ID NO: 16.3. The antibody claim 1 , or antigen-binding portion thereof claim 1 , of claim 1 , wherein the heavy chain CDR1 claim 1 , CDR2 claim 1 , and CDR3 regions respectively comprise the amino acid sequences of:(a) SEQ ID NOs: 13, 14, and 15;(b) SEQ ID NOs: 25, 26, and 27;(c) SEQ ID NOs: 37, 38, and 39;(d) SEQ ID NOs: 49, 50, and 51;(e) SEQ ID NOs: 61, 62, and 63;(f) SEQ ID NOs: 73, 74, and 75;(g) SEQ ID NOs: 85, 86, and 87;(h) SEQ ID NOs: 97, 98, and 99;(i) SEQ ID NOs: 109, 110, and 111;(j) SEQ ID NOs: 121, 122, and 123;(k) SEQ ID NOs: 133, 134, and 135; or(l) SEQ ID NOs: 145, 146, and 147.4. The antibody claim 1 , or antigen-binding portion thereof claim 1 , ...

TL1A ANTIBODIES AND USES THEREOF

Disclosed are antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. 1. A method for treating a subject afflicted with an inflammatory or immune system disease comprising administering to the subject a therapeutically effective amount of an antibody or an antigen binding fragment thereof that binds specifically to TNF-like ligand 1A (TL1A).2. The method of claim 1 , wherein the antibody claim 1 , or antigen binding fragment thereof binds to both human and cynomolgus TL1A.3. The method of claim 1 , wherein the antibody claim 1 , or antigen binding fragment thereof comprises: CDRH1 comprising the sequence of SEQ ID NO:7;', 'CDRH2 comprising the sequence of SEQ ID NO:8; and', 'CDRH3 comprising the sequence of SEQ ID NO:9;, 'a) a heavy chain variable domain comprisingand CDRL1 comprising the sequence of SEQ ID NO:12;', 'CDRL2 comprising the sequence of SEQ ID NO:13; and', 'CDRL3 comprising the sequence of SEQ ID NO:14;, 'b) a light chain variable domain comprisingwherein the antibody or fragment inhibits the binding of human TL to DR3.4. The method of claim 1 , wherein the antibody claim 1 , or antigen binding fragment thereof binds to TL1A (SEQ ID NO:20) at an epitope comprising one or more of residues 102-116 (SEQ ID NO:16) or 166-180 (SEQ ID NO: 17).5. The method of claim 3 , wherein the antibody claim 3 , or antigen binding fragment thereof binds to TL1A at an epitope comprising one or more of residues QAGR(SEQ ID NO:21) and one or more of residues KNQF(SEQ ID NO:22).6. The method of claim 4 , wherein the antibody claim 4 , or antigen binding fragment thereof binds to TL1A at an epitope comprising the sequence QAGR(SEQ ID NO:21) and/or KNQF(SEQ ID NO:22).7. The method of claim 1 , wherein the antibody claim 1 , or antigen binding fragment thereof comprises one or more heavy chains and one or more light chains claim 1 , wherein:a) the heavy ...

Anti-gitr antibodies for cancer diagnostics

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

ANTIBODIES AGAINST TIM3 AND USES THEREOF

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof. 124-. (canceled)25. An isolated antibody , which binds to a human TIM3 , comprising a heavy chain CDR1 , CDR2 , and CDR3 and a light chain CDR1 , CDR2 , and CDR3 , wherein:(a1) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 41, 46, and 53, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 68, respectively;(a2) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 41, 122, and 53, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 68, respectively;(a3) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 41, 123, and 53, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 68, respectively;(a4) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 41, 124, and 53, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 68, respectively;(a5) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 41, 46, and 126, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 68, respectively;(a6) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 41, 46, and 127, respectively, and the light chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 64, 66, and 68, respectively;(a7) the heavy chain CDR1, CDR2, and CDR3 comprise SEQ ID NOs: 41, 46, and ...

SUCTION SEAT FOR INTELLIGENT NURSING TOILET BOWL

The invention discloses a suction seat for an intelligent nursing toilet bowl. The suction seat comprises a housing installed on a base, the interior of the housing is an inner cavity, a temperature and humidity sensor, an excrement sensor and a flushing nozzle are respectively installed in the cavity body of the inner cavity, a urine sensor is arranged on the outer side of the lower part of the cavity body, and a discharge port connected with an external negative pressure pipeline is vertically formed in the bottom of the cavity body; and a cleaning device and a ventilation device which are communicated with the interior of the cavity body are arranged on the outer side of the rear part of the cavity body. The cleaning device can automatically adjust the height of the nozzle as well as the pressure and flow rate of running water, thereby realizing overall cleaning on human hip, and overcoming the defects that the existing nozzle is fixed and the flushing area cannot be adjusted. Since the temperature and humidity sensor is arranged inside the suction seat, optimal skin comfort is achieved by adjusting air parameters under the circumstance that neither excrement nor urine is generated. The whole suction seat is compact in structure, and high cleanness of the inner cavity is kept after long-term use; and the whole suction seat adopting the structural design conforming to ergonomics achieves an optimal using effect. 1. A suction seat for an intelligent nursing toilet bowl , comprising a housing installed on a base , wherein the interior of the housing is an inner cavity , a temperature and humidity sensor , an excrement sensor and a flushing nozzle are respectively installed in the cavity body of the inner cavity , a urine sensor is arranged on the outer side of the lower part of the cavity body , and a discharge port connected with an external negative pressure pipeline is vertically formed in the bottom of the cavity body; a cleaning device and a ventilation device ...

ANTI-NKG2A ANTIBODIES AND USES THEREOF

The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided. 1. An isolated monoclonal antibody , or antigen-binding fragment thereof , that specifically binds to human natural killer cell inhibitory receptor group 2A (NKG2A) protein , comprising:(a) a heavy chain variable domain comprising amino acid sequences of SEQ ID NOs: 10, 11, 12, and a light chain variable domain comprising amino acid sequences of SEQ ID NOs: 13, 14, and 15;(b) a heavy chain variable domain comprising amino acid sequences of SEQ ID NOs: 10, 11, and 12, and a light chain variable domain comprising amino acid sequences of SEQ ID NOs: 154, 14, and 15; or(c) a heavy chain variable domain comprising amino acid sequences of SEQ ID NOs: 10, 11, and 12, and a light chain variable domain comprising amino acid sequences of SEQ ID NOs: 155, 14, and 15.2. An isolated monoclonal antibody , or antigen-binding fragment thereof , that specifically binds to human NKG2A protein , and comprises heavy and light chain variable regions , wherein:(a) the heavy chain variable region comprises an amino acid sequence that is at least about 80%, at least about ...

Method, Terminal And System For Transmitting File Between Multiple Terminals

A method, terminal, and system for transmitting a file between multiple terminals is described. The method includes obtaining a picture, which is photographed by a file receiving end from a file sending end from a file sending end and includes a to-be-transmitted file, and performing image recognition on the obtained picture to determine the to-be-transmitted file of the file sending end, the picture of the to-be-transmitted file being displayed on a display interface of the file sending end. The method further includes determining a file path of the to-be-transmitted file according to the determined to-be-transmitted file, obtaining the to-be-transmitted file according to the file path of the to-be-transmitted file, and transmitting the to-be-transmitted file to the file receiving end. 1. A method for transmitting a file between multiple terminals , used for transmitting a file between multiple independent terminals , the method comprising:obtaining a picture, which is photographed by a file receiving end from a file sending end and comprises a to-be-transmitted file, and performing image recognition on the obtained picture to determine the to-be-transmitted file of the file sending end, the picture comprising the to-be-transmitted file being displayed on a display interface of the file sending end;determining a file path of the to-be-transmitted file according to the determined to-be-transmitted file; andobtaining the to-be-transmitted file according to the file path of the to-be-transmitted file, and transmitting the to-be-transmitted file to the file receiving end.2. The method according to claim 1 , wherein the obtaining a picture claim 1 , which is photographed by a file receiving end from a file sending end from a file sending end and comprises a to-be-transmitted file comprises:obtaining the picture, which is photographed by the file receiving end from the file sending end and comprises the to-be-transmitted file, by using a server, wherein the picture is ...

Antibodies against il-7r alpha subunit and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Antibodies against cd73

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

MAGNETIC BEAD PURIFICATION SYSTEM

The present invention provides a magnetic bead purification system, including: a housing; a liquid path treatment system provided inside the housing, the liquid path treatment system being connectable to a reagent barrel and a waste liquid barrel; a sample addition needle group connected to the liquid path treatment system, the sample addition needle group being movable within the housing and connected to the liquid path treatment system, so as to receive a reagent from the liquid path treatment system or to discharge a waste liquid to the liquid path treatment system; a purification magnetic separation system, including a magnetic element, the purification magnetic separation system being controllable to apply a lateral magnetic force to a purification treatment position inside the housing or stop the application of the magnetic force by the magnetic element; and a purification station system movable between a purification treatment position inside the housing and a loading position outside the housing, the purification station system being adapted to load a container. The magnetic bead purification system of the present invention can easily achieve large capacity sample treatment. 1. A magnetic bead purification system , comprising:a housing;a liquid path treatment system provided inside the housing, the liquid path treatment system being connectable to a reagent barrel and a waste liquid barrel;a sample addition needle group connected to the liquid path treatment system, the sample addition needle group being movable within the housing and connected to the liquid path treatment system, so as to receive a reagent from the liquid path treatment system or to discharge a waste liquid to the liquid path treatment system;a purification magnetic separation system, comprising a magnetic element, the purification magnetic separation system being controllable to apply a lateral magnetic force to a purification treatment position inside the housing or stop the application ...

ANTIBODIES AGAINST TIM3 AND USES THEREOF

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof. 1. An isolated antibody (e.g. , a human antibody) , or antigen binding portion thereof , which binds to human T-cell immunoglobulin and mucin-domain containing-3 (TIM3) and exhibits the following properties:(a) binds to soluble human TIM3;(b) binds to membrane bound human TIM3;(c) induces or enhances T cell activation; and optionally:(d) binds to soluble cynomolgus TIM3; and(e) binds to membrane cynomolgus TIM3.2. The antibody claim 1 , or antigen binding portion thereof claim 1 , of claim 1 , wherein the antibody stimulates an anti-tumor immune response.3. The antibody claim 1 , or antigen binding portion thereof claim 1 , of or claim 1 , wherein the antibody stimulates an antigen-specific T cell response.4. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody increases IFN-γ production in TIM3-expressing T cells.5. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody increases T cell proliferation.6. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody does not bind to Fc receptors claim 1 , or wherein the antibody lacks effector function.7. The antibody claim 1 , or antigen binding portion ...

CONTROL METHOD OF RADIOFREQUENCY SOURCE

The present disclosure provides a radio frequency (RF) source control method. An RF source includes at least one pair of a main power supply and a secondary power supply with a same frequency. The RF source control method includes dividing each process step of process steps of a plasma process into a plurality of time periods, and when performing each process step, maintaining a common exciter (CEX) phase locking delay angle of the at least one pair of the main power supply and the secondary power supply corresponding to each of the time periods at a predetermined value to provide an increased angular distribution uniformity of plasma. The RF source control method provided by the present disclosure may be used to adjust plasma distribution above a to-be-processed workpiece to average the plasma angular direction distribution of the entire process step as a whole to increase process uniformity of the to-be-processed workpiece. 1. A radio frequency (RF) source control method , comprising:dividing each process step of process steps of a plasma process into a plurality of time periods; andwhen performing each process step, maintaining a common exciter (CEX) phase locking delay angle of at least a pair of a main power supply and a secondary power supply corresponding to each of the time periods at a predetermined value to provide an increased plasma angular distribution uniformity, the main power supply and the secondary power supply having a same frequency.2. The method according to claim 1 , wherein predetermined values of the CEX phase locking delay angle corresponding to the plurality of time periods are distributed non-time periodically in each process step.3. The method according to claim 1 , wherein predetermined values of the CEX lock phase angel of adjacent time periods are different in each process step.4. The method according to claim 1 , further comprising:according to a process condition of each process step, respectively determining a quantity of the ...

COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody. 164-. (canceled)65. A method of treating cancer in a subject having a tumor that expresses CD73 , comprising administering to the subject a therapeutically effective amount of a CD73 antagonist and an immuno-oncology agent , wherein(a) the CD73 antagonist is administered at a dose of about 150 mg to about 1600 mg, and the immuno-oncology agent is administered at a dose of about 50 mg to about 500 mg, once per week, once every 2 weeks, once every 3 weeks, or once every 4 four weeks, or(b) the CD73 antagonist is administered at a dose of about 150 mg to about 1600 mg once per week and the immuno-oncology agent is administered at a dose of about 50 mg to about 500 mg once every 2 weeks, once every 3 weeks or once every 4 four weeks.66. The method of claim 65 , wherein(a) the CD73 antagonist is administered at a dose of about 600 mg once per week or once every 2 weeks, and(b) the immuno-oncology agent is administered at about 240 mg once every 2 weeks or at about 480 mg once every 4 weeks.67. The method of claim 65 , wherein the CD73 antagonist and the immuno-oncology agent are administered for 1 to 10 cycles claim 65 , wherein each cycle is a period of 28 days.68. The method of claim 65 , wherein the CD73 antagonist and the immuno-oncology agent are administered on the same day.69. The method of claim 65 , wherein the CD73 antagonist and immuno-oncology agent are formulated for intravenous administration.70. The method of claim 65 , wherein the CD73 antagonist and immuno-oncology agent are formulated separately.71. The method of claim 65 , wherein the CD73 antagonist and immuno-oncology agent are formulated together.72. The method of claim 65 , wherein the CD73 antagonist is administered prior to administration of the immuno-oncology agent.73. The method of claim 65 , wherein the ...

Dicaffeoyl Spermidine Derivative Glycosides And Use Thereof

The present invention relates to dicaffeoyl spermidine derivative glycosides, a preparation method and a use thereof. The biological activity experiments show that the dicaffeoyl spermidine derivative glycosides of the present invention have anti-oxidative activity and antiviral activity, and their activity are even better than that of a positive control drug, thus can be used as an antioxidant for the prevention and/or treatment of neurodegenerative diseases such as Senile dementia, and as an antiviral agent for the prevention and/or treatment of viral infections. 2. The dicaffeoyl spermidine derivative glycosides or the pharmaceutically acceptable salts thereof according to claim 1 , wherein the pharmaceutically acceptable salts are salts formed by the dicaffeoyl spermidine derivative glycosides of the formula (I) with an inorganic acid or an organic acid.3. The dicaffeoyl spermidine derivative glycosides or the pharmaceutically acceptable salts thereof according to claim 2 , wherein the inorganic acid is hydrochloric acid claim 2 , hydrobromic acid claim 2 , sulfuric acid claim 2 , or nitric acid claim 2 , and the organic acid is trifluoroacetic acid claim 2 , acetic acid claim 2 , propionic acid claim 2 , malonic acid claim 2 , butyric acid claim 2 , lactic acid claim 2 , methanesulfonic acid claim 2 , ethanesulfonic acid claim 2 , benzenesulfonic acid claim 2 , p-toluenesulfonic acid claim 2 , maleic acid claim 2 , benzoic acid claim 2 , succinic acid claim 2 , picric acid claim 2 , tartaric acid claim 2 , citric acid claim 2 , or fumaric acid.57.-. (canceled)8. A pharmaceutical composition claim 1 , comprising the dicaffeoyl spermidine derivative glycosides or the pharmaceutically acceptable salts thereof according to as an active ingredient claim 1 , and pharmaceutically acceptable excipients.9. The pharmaceutical composition according to claim 8 , wherein the content of the dicaffeoyl spermidine derivative glycosides or the pharmaceutically acceptable salts ...

ANTIBODIES AGAINST TIM3 AND USES THEREOF

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof. 1. An isolated antibody (e.g. , a human antibody) , or antigen binding portion thereof , which binds to human T-cell immunoglobulin and mucin-domain containing-3 (TIM3) and exhibits the following properties:(a) binds to soluble human TIM3;(b) binds to membrane bound human TIM3;(c) induces or enhances T cell activation; and optionally;(d) binds to soluble cynomolgus TIM3; and(e) binds to membrane cynomolgus TIM3.2. The antibody claim 1 , or antigen binding portion thereof claim 1 , of claim 1 , wherein the antibody stimulates an anti-tumor immune response.3. The antibody claim 1 , or antigen binding portion thereof claim 1 , of or claim 1 , wherein the antibody stimulates an antigen-specific T cell response.4. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody increases IFN-γ production in TIM3-expressing T cells.5. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody increases T cell proliferation.6. The antibody claim 1 , or antigen binding portion thereof claim 1 , of any one of the preceding claims claim 1 , wherein the antibody does not bind to Fc receptors claim 1 , or wherein the antibody lacks effector function.7. The antibody claim 1 , or antigen binding portion ...

ANTI-TREM-1 ANTIBODIES AND USES THEREOF

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases. 1. An isolated antibody which specifically binds to a triggering receptor expressed on myeloid cells-1 (TREM-1) , comprising a heavy chain variable region (VH) , a light chain variable region (VL) , and an IgG1 heavy chain constant region , wherein the IgG1 heavy chain constant region comprises one or more amino acid substitutions compared to a wild-type IgG1 heavy chain constant region (SEQ ID NO: 9).24-. (canceled)5. The antibody of claim 1 , wherein the antibody specifically binds to a TREM-1 epitope comprising amino acids D38 to L45 claim 1 , E46 to Q56 claim 1 , and/or Y90 to L96 of SEQ ID NO: 1.6. The antibody of claim 1 , (i) wherein the IgG1 heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of K214R claim 1 , L234A claim 1 , L235E claim 1 , G237A claim 1 , D356E claim 1 , and L358M claim 1 , per EU numbering; (ii) wherein the IgG1 heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of K214R claim 1 , L234A claim 1 , L235E claim 1 , G237A claim 1 , A330S claim 1 , P331S claim 1 , D356E claim 1 , and L358M claim 1 , per EU numbering; (iii) wherein the IgG1 heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of K214R claim 1 , C226S claim 1 , C229S claim 1 , and P238S claim 1 , per EU numbering; or (iv) wherein the IgG1 heavy chain constant region comprises one or more amino acid substitutions selected from the group consisting of S131C claim 1 , K133R claim 1 , G137E claim 1 , G138S claim 1 , ...

ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies. 1. An isolated monoclonal antibody , or antigen binding portion thereof , which binds to human glucocorticoid-inducible TNF receptor (GITR) , comprising heavy chain CDR1 , CDR2 , and CDR3 sequences comprising SEQ ID NOs: 20 , 21 , and 22 , respectively , and light chain CDR1 , CDR2 , and CDR3 sequences comprising SEQ ID NOs: 23 , 24 , and 25 , respectively.24-. (canceled)5. The antibody claim 1 , or antigen binding portion thereof claim 1 , of claim 1 , wherein the antibody stimulates a T cell response.6. The antibody claim 1 , or antigen binding portion thereof claim 1 , of claim 1 , wherein the antibody binds to soluble human GITR with a Kof 10 nM or less as measured by Biacore.7. The isolated monoclonal antibody claim 1 , or antigen binding portion thereof claim 1 , of claim 1 , which comprises heavy and light chain variable region sequences set forth in SEQ ID NOs: 13 and 14 claim 1 , respectively.810-. (canceled)1218-. (canceled)19. A nucleic acid encoding the heavy and/or light chain variable region of the antibody claim 1 , or antigen binding portion thereof claim 1 , of .20. A composition comprising the antibody claim 1 , or antigen binding portion thereof claim 1 , of and a carrier.21. A composition comprising the antibody claim 1 , or antigen binding portion thereof claim 1 , of and one or more additional therapeutics.22. The composition of claim 21 , wherein the one or more additional therapeutics are selected from the group consisting of: an anti-PD1 antibody claim 21 ...

A chemical mechanical polishing paste for tantalum barrier layer

A chemical mechanical polishing paste for tantalum barrier layer is disclosed, which comprises abrasive particles A, abrasive particles B with larger particle size than A, triazoles compound, organic acid and carrier. The present chemical mechanical polishing paste can significantly reduce defect, scratch, contaminant and other residual, and adjust the polishing selectivity for barrier and oxide layers by using different particles size. As a result, it solves the problem of difficultly adjusting the removing rate of two substrate separately, prevents the local and general corrosion during metal polishing, hence increases the acceptable quality level.

Chemical Mechanical Polishing Paste for Tantalum Barrier Layer

A chemical mechanical polishing slurry for Ta barrier layer is disclosed, which comprises abrasive particles A, abrasive particles B larger in size than abrasive particles A, a triazole compound, an organic acid and a carrier. By using the chemical mechanical polishing slurry according to the present invention, the defects, scratches, contaminants and other residues can be reduced significantly, and the polishing selectivity between the barrier layer and the oxide layer can be adjusted by using particles of different sizes, so that the difficulty of adjusting the removing rates of two substrates separately is overcome. Furthermore, both the local corrosion and the general corrosion during the metal polishing process are avoided, and thus the yield rate of the desired products is promoted.

A chemical-mechanical polishing liquid for polishing low-dielectric material

A chemical-mechanical polishing liquid for polishing low-dielectric material is disclosed, which comprises abrasive particles, corrosion inhibitor, oxidizer and water, and the characteristic of the liquid is in that further comprises at least one kind of accelerator. The polishing liquid have higher removal rate for low-dielectric material under lower pressure, and also have higher removal rate for other material such as metal copper (Cu), silica (Teos), metal tantalum (Ta)/ tantalum nitride (TaN) barrier and the like.

Polishing slurry for low dielectric material

A polishing slurry for low dielectric material is disclosed. It includes abrasive and water, and is characterized in that, it further contains one or more kinds of metal chelating agents, azole-species as film-forming agent and oxidizing agent. Under lower pressure, the present polishing slurry has higher polishing speed on low dielectric material, suitable polishing selectivity for other materials, and better surface finish after polishing.

Polishing slurry for subtle surface planarization and its using method

A polishing slurry for subtle surface planarization and its using method are disclosed. The present polishing slurry for subtle surface planarization includes abrasive and water, it is characterized in that the abrasive is a colloidal Al-doped silica abrasive, this colloidal Al-doped silica abrasive is an aqueous dispersion of Al-doped silica. When using the present polishing slurry for subtle surface planarization in CMP process, the downward pressure is 0.5-3psi. The present polishing slurry for subtle surface –planarization can effectively polish Ta, TaN, TEOS, FSG, BD or other lower dielectric material and so on, and the polishing rate for lower dielectric material can be increased by two times, while excellent planarization effect can be obtained.

Polishing slurry containing blended abrasives for low dielectric material

A polishing slurry containing blended abrasives for low dielectric material is disclosed, which includes two or more kinds of polishing abrasives, wherein, one of the abrasives is Al-doped silica, and the second abrasive is the one selected from silica, alumina, alumina -coated silica or zirconia-coated silica or their combinations. The present polishing slurry not only can effectively adjust the polishing speed of low dielectric carbon-doped silica (CDO) and silica, but also can prevent local and throughout corrosion during metal polishing, thus can improve the acceptability. Moreover, it is useful in integrate circuit which contains metal,metal barrier, carbon-doped silica and silica simultaneously.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid- inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against cd73 and uses thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Combination therapy with anti-cd73 antibodies

Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD- 1 antibody.

Antibodies against tim3 and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against tim3 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

Anti-trem-1 antibodies and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Antibodies against il-7r alpha subunit and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

Glypican-3 binding fibronectin based scafflold molecules

Provided herein are polypeptides which include tenth fibronectin type III domains (¹⁰Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a¹⁰Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3¹⁰Fn3 drug conjugates are also provided.

Antibodies against MICA and/or MICB and uses thereof

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against cd73 and uses thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against TIM3 and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Anti-TREM-1 antibodies and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcγRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

Antibodies against IL-7R alpha subunit and uses thereof

Provided herein are antibodies that bind to the alpha subunit of an IL-7 receptor (IL-7Rα). Also provided are uses of these antibodies in therapeutic applications, such as treatment of inflammatory diseases. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain regions of the antibodies, and vectors comprising the polynucleotides.

CD73 Antibodies and Their Uses

Un anticuerpo aislado que se une a Grupo de Diferenciación 73 (CD73) humano y que comprende las secuencias CDR1, CDR2 y CDR3 de la cadena pesada que comprenden las SEQ ID NO: 5, 6 y 7, respectivamente, y las secuencias CDR1, CDR2 y CDR3 de la cadena ligera que comprenden las SEQ ID NO: 13, 14 y 15, respectivamente, en donde el anticuerpo comprende una región constante de la cadena pesada que comprende una bisagra de IgG2 y dominio CH1 de IgG2. An isolated antibody that binds to human Differentiation Group 73 (CD73) and comprises the heavy chain sequences CDR1, CDR2 and CDR3 comprising SEQ ID NO: 5, 6 and 7, respectively, and the CDR1, CDR2 sequences and CDR3 of the light chain comprising SEQ ID NO: 13, 14 and 15, respectively, wherein the antibody comprises a constant region of the heavy chain comprising a hinge of IgG2 and CH1 domain of IgG2.

Glypican-3binding fibronectin based scafflold molecules

Antibodies against mica and/or micb and uses thereof

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

抗ｃｄ７３抗体を用いた併用療法

【課題】ＣＤ７３を発現する腫瘍を有する癌を治療する方法を提供する。【解決手段】抗ＣＤ７３抗体を、免疫－腫瘍学薬剤、具体的には、ＰＤ－１アンタゴニスト、ＰＤ－Ｌ１アンタゴニスト、ＣＴＬＡ－４アンタゴニスト及びＬＡＧ－３アンタゴニストと組み合わせて使用する、肺腺癌、甲状腺癌腫、膵臓腺癌、子宮内膜癌腫、結腸腺癌、肺扁平上皮細胞癌腫、頭頸部扁平上皮細胞癌腫および卵巣腺癌からなる群から選択される腫瘍の臨床治療のための方法を提供する。【選択図】なし

Anti-trem-1 antibodies and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more FcRs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.

一种桶装矿泉水生产装置

本实用新型公开了一种桶装矿泉水生产装置，具体涉及矿泉水技术领域，包括两个支撑板，所述支撑板的内部设有空腔，两个所述支撑板的相对一侧均设有第一下降槽，两个所述支撑板的相背一侧均设有第二下降槽，所述第一下降槽和第二下降槽的相对一侧均与空腔相连通，所述支撑板的顶部设有连接板，所述连接板的顶部设有伸缩杆。本实用新型通过设有伸缩杆和弹簧，利用灌水的时候，桶装矿泉水不断增重，带动伸缩杆不断下压，带动第一连接杆往下移动，挡水板在空槽内也逐渐下压，一直到挡水板的挡住了出水口，这样经过一系列的配合，解决了传统桶装矿泉水生产过程中还需要手动关闭出水口的问题，提高了工作效率。

ANTIBODIES BINDING TO VISTA AT ACIDIC pH

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

anti tl1a antibodies and uses thereof

a presente invenção refere-se a anticorpos que se ligam especificamente ao membro 15 da superfamília de tnf (tnfsf15) receptor, também conhecido como tl1a. a presente invenção também se refere a métodos de fabricação e utilização dos anticorpos anti-tl1a. The present invention relates to antibodies that specifically bind to receptor 15 of the receptor tnf (tnfsf15) superfamily, also known as t11a. The present invention also relates to methods of making and using anti-T1a antibodies.

Anti-nkg2a antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies ( e.g ., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody ( e.g. , anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Antibodies against tim3 and uses thereof

【課題】がんの免疫療法を改善するための、ＴＩＭ３を標的とする薬剤を提供する。【解決手段】ヒトＴ細胞免疫グロブリンおよびムチンドメイン含有３（ＴＩＭ３）と結合する、単離された抗体（例えば、ヒト抗体）またはその抗原結合部分であって、以下の特性：（ａ）可溶性ヒトＴＩＭ３と結合すること、（ｂ）膜結合型ヒトＴＩＭ３と結合すること、（ｃ）Ｔ細胞活性化を誘導または増強すること、ならびに適宜（ｄ）可溶性カニクイザルＴＩＭ３と結合すること、および（ｅ）膜カニクイザルＴＩＭ３と結合することを示す、抗体またはその抗原結合部分を使用する。【選択図】なし

Anti human ip-10 antibodies and their uses

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

Antibodies binding to ilt4

The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

Antibodies binding to vista at acidic ph

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Anti-nkg2a antibodies and uses thereof

The present disclosure provides isolated monoclonal antibodies ( e.g ., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody ( e.g. , anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Anti-GITR antibodies for cancer diagnostics

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against CD73 and uses thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.